WebMD Health (WBMD) 10-K 29 Feb 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Feb. 19, 2016	Jun. 30, 2015
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Trading Symbol	WBMD
Entity Registrant Name	WEBMD HEALTH CORP.
Entity Central Index Key	1,326,583
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		38,015,720
Entity Public Float			$ 1,572,977,000

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 641,165	$ 706,776
Accounts receivable, net of allowance for doubtful accounts of $1,040 at December 31, 2015 and $631 at December 31, 2014	174,313	136,806
Prepaid expenses and other current assets	18,998	13,877
Deferred tax assets	16,126	18,147
Total current assets	850,602	875,606
Property and equipment, net	81,027	59,573
Goodwill	202,980	202,980
Intangible assets, net	10,894	14,215
Deferred tax assets		18,947
Other assets	20,464	26,236
TOTAL ASSETS	1,165,967	1,197,557
Current liabilities:
Accrued expenses	80,664	72,658
Deferred revenue	102,715	89,785
Total current liabilities	286,061	162,443
Other long-term liabilities	$ 23,678	$ 21,293
Commitments and contingencies
Stockholders' equity:
Preferred stock, 50,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.01 par value per share, 650,000,000 shares authorized; 57,437,992 shares issued at December 31, 2015 and December 31, 2014	$ 574	$ 574
Additional paid-in capital	9,238,444	9,214,800
Treasury stock, at cost; 20,621,216 shares at December 31, 2015 and 21,084,995 shares at December 31, 2014	(678,069)	(685,659)
Accumulated other comprehensive income	357	976
Accumulated deficit	(8,405,078)	(8,469,102)
Stockholders' equity	156,228	61,589
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	1,165,967	1,197,557
2.25% Convertible Notes Due 2016 [Member]
Current liabilities:
convertible notes current	102,682
Convertible notes		252,232
2.50% Convertible Notes Due 2018 [Member]
Current liabilities:
Convertible notes	400,000	400,000
1.50% Convertible Notes Due 2020 [Member]
Current liabilities:
Convertible notes	$ 300,000	$ 300,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Accounts receivable, net of allowance for doubtful accounts	$ 1,040	$ 631
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	650,000,000	650,000,000
Common stock, shares issued	57,437,992	57,437,992
Treasury stock, shares	20,621,216	21,084,995

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Revenue	$ 192,129	$ 152,607	$ 148,320	$ 143,343	$ 162,727	$ 143,490	$ 140,400	$ 133,832	$ 636,399	$ 580,449	$ 515,293
Cost of operations	69,475	59,552	60,407	57,877	60,676	56,398	54,456	52,564	247,311	224,094	209,740
Sales and marketing	40,129	32,850	32,570	32,476	36,978	32,950	33,321	32,911	138,025	136,160	127,997
General and administrative	24,183	22,942	23,002	21,453	24,756	23,243	22,339	23,781	91,580	94,119	93,220
Depreciation and amortization	7,418	7,266	7,592	8,245	7,774	7,667	7,042	7,328	30,521	29,811	26,606
Interest income	15	10	9	17	18	19	17	15	51	69	76
Interest expense	5,099	5,681	6,171	6,172	6,171	6,171	6,172	6,172	23,123	24,686	22,826
Loss on convertible notes		2,058							2,058		4,871
Gain on investments			139						139
Other expense			4,100						4,100		1,353
Income from continuing operations before income tax provision	45,840	22,268	14,626	17,137	26,390	17,080	17,087	11,091	99,871	71,648	28,756
Income tax provision	18,379	9,080	1,255	7,133	11,236	7,275	7,371	4,825	35,847	30,707	13,640
Income from continuing operations					15,154	9,805	9,716	6,266	64,024	40,941	15,116
Income from discontinued operations, net of a tax					1,122					1,122
Net income	$ 27,461	$ 13,188	$ 13,371	$ 10,004	$ 16,276	$ 9,805	$ 9,716	$ 6,266	$ 64,024	$ 42,063	$ 15,116
Basic income per common share:
Income from continuing operations	$ 0.75	$ 0.36	$ 0.36	$ 0.27	$ 0.42	$ 0.26	$ 0.26	$ 0.16	$ 1.75	$ 1.08	$ 0.32
Income from discontinued operations					0.03					0.03
Net income					0.45	0.26	0.26	0.16	1.75	1.11	0.32
Diluted income per common share:
Income from continuing operations	$ 0.60	$ 0.32	$ 0.32	$ 0.25	0.36	0.23	0.23	0.15	1.48	0.97	0.31
Income from discontinued operations					0.02					0.03
Net income					$ 0.38	$ 0.23	$ 0.23	$ 0.15	$ 1.48	$ 1	$ 0.31
Weighted-average shares outstanding used in computing per share amounts:
Basic	36,583	36,721	36,705	36,393	36,427	37,960	37,819	39,268	36,600	37,869	46,830
Diluted	51,338	49,958	53,618	43,465	53,082	45,757	45,801	41,852	52,653	45,614	48,398

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Statement of Comprehensive Income [Abstract]
Net income	$ 64,024	$ 42,063	$ 15,116
Other comprehensive (loss) income, net of tax:
Unrealized (loss) gain on available-for-sale securities	(619)	976
Total other comprehensive (loss) income, net of tax	(619)	976
Comprehensive income	$ 63,405	$ 43,039	$ 15,116

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]	Tender Offer [Member]	Tender Offer [Member]Common Stock [Member]	Tender Offer [Member]Additional Paid-In Capital [Member]	Tender Offer [Member]Treasury Stock [Member]
Balances at Dec. 31, 2012	$ 509,989	$ 624	$ 9,489,099	$ (453,453)		$ (8,526,281)
Balances, Shares at Dec. 31, 2012		62,437,992		13,425,144
Net income	15,116					15,116
Issuance of stock for option exercises and other issuances, Value	17,796		(83,165)	$ 100,961
Issuance of stock for option exercises and other issuances, Shares				(1,938,041)
Tax benefit realized from issuances of common stock	58		58
Stock-based compensation expense	38,186		38,186
Repurchase of shares, Value	(219,729)			$ (219,729)			$ (170,516)	$ (50)	$ (170,466)
Repurchase of shares, Shares				6,794,395
Repurchase of shares, Shares								(5,000,000)
Balances at Dec. 31, 2013	190,900	$ 574	9,273,712	$ (572,221)		(8,511,165)
Balances, Shares at Dec. 31, 2013		57,437,992		18,281,498
Net income	42,063					42,063
Other comprehensive income, net of tax	976				$ 976
Issuance of stock for option exercises and other issuances, Value	7,516		(105,382)	$ 112,898
Issuance of stock for option exercises and other issuances, Shares				(2,356,573)
Tax benefit realized from issuances of common stock	14,239		14,239
Stock-based compensation expense	32,231		32,231
Repurchase of shares, Value	(128,748)			$ (128,748)			$ (97,588)			$ (97,588)
Repurchase of shares, Shares				3,160,070						2,000,000
Balances at Dec. 31, 2014	61,589	$ 574	9,214,800	$ (685,659)	976	(8,469,102)
Balances, Shares at Dec. 31, 2014		57,437,992		21,084,995
Net income	64,024					64,024
Other comprehensive income, net of tax	(619)				(619)
Issuance of stock for option exercises and other issuances, Value	16,861		(19,135)	$ 35,996
Issuance of stock for option exercises and other issuances, Shares				(1,152,246)
Tax benefit realized from issuances of common stock	39,002		39,002
Correcting adjustment to prior years' tax benefits realized from issuances of common stock	(29,499)		(29,499)
Stock-based compensation expense	33,276		33,276
Repurchase of shares, Value	(28,406)			$ (28,406)
Repurchase of shares, Shares				688,467
Balances at Dec. 31, 2015	$ 156,228	$ 574	$ 9,238,444	$ (678,069)	$ 357	$ (8,405,078)
Balances, Shares at Dec. 31, 2015		57,437,992		20,621,216

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net income	$ 64,024	$ 42,063	$ 15,116
Adjustments to reconcile net income to net cash provided by operating activities:
Income from discontinued operations, net of tax		(1,122)
Depreciation and amortization	30,521	29,811	26,606
Non-cash interest, net	4,172	4,511	4,192
Non-cash stock-based compensation	33,743	32,546	38,550
Deferred income taxes	(7,713)	14,717	13,070
Loss on convertible notes	2,058		4,871
Gain on investments	(139)
Changes in operating assets and liabilities:
Accounts receivable	(37,507)	(12,574)	(17,610)
Prepaid expenses and other, net	(4,132)	(673)	266
Accrued expenses and other long-term liabilities	9,606	(380)	8,061
Deferred revenue	12,930	4,637	(7,028)
Net cash provided by continuing operations	107,563	113,536	86,094
Net cash used in discontinued operations		(384)
Net cash provided by operating activities	107,563	113,152	86,094
Cash flows from investing activities:
Cash paid in business combination		(3,182)
Proceeds from sale of investments	139
Purchases of property and equipment	(48,372)	(23,194)	(22,341)
Proceeds from sale of property and equipment			1,381
Net cash used in investing activities	(48,233)	(26,376)	(20,960)
Cash flows from financing activities:
Proceeds from exercise of stock options	21,939	40,602	29,724
Cash used for withholding taxes due on stock-based awards	(6,438)	(33,385)	(12,526)
Net proceeds from issuance of convertible notes			291,823
Repurchase of convertible notes	(151,038)		(150,354)
Repurchase of shares through tender offers		(97,588)	(170,516)
Purchases of treasury stock	(28,406)	(128,748)	(220,298)
Excess tax benefit on stock-based awards	39,002	14,239	58
Net cash used in financing activities	(124,941)	(204,880)	(232,089)
Net decrease in cash and cash equivalents	(65,611)	(118,104)	(166,955)
Cash and cash equivalents at beginning of period	706,776	824,880	991,835
Cash and cash equivalents at end of period	$ 641,165	$ 706,776	$ 824,880

Background and Basis of Present

Background and Basis of Presentation	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Background and Basis of Presentation	1. Background and Basis of Presentation Background WebMD Health Corp. (the “Company” or “WebMD”) is a Delaware corporation that was incorporated on May 3, 2005. The Company completed an initial public offering on September 28, 2005. The Company’s Common Stock trades under the symbol “WBMD” on the Nasdaq Global Select Market. The Company generates revenue from the advertising and sponsorship services of The WebMD Health Network WebMD Health Services Advertising and Sponsorship The WebMD Health Network www.WebMD.com www.Medscape.com WebMD Magazine Private Portal Services WebMD Health Services WebMD Health Services WebMD Health Services WebMD Health Services Information Services. Basis of Presentation The accompanying Consolidated Financial Statements include the consolidated accounts of the Company and its wholly-owned subsidiaries and have been prepared in United States dollars, and in accordance with U.S. generally accepted accounting principles (“GAAP”). The results of operations for companies acquired or disposed of are included in the Consolidated Financial Statements from the effective date of acquisition or up to the date of disposal. All material intercompany balances and transactions have been eliminated in consolidation.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Accounting Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. The Company bases its estimates on historical experience, current business factors, and various other assumptions that the Company believes are necessary to consider to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company’s business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment changes. Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in reported results of operations; if material, the effects of changes in estimates are disclosed in the notes to the Consolidated Financial Statements. Significant estimates and assumptions by management affect the allowance for doubtful accounts, the carrying value of long-lived assets (including goodwill and intangible assets), the amortization period of long-lived assets (excluding goodwill and indefinite-lived intangible assets), the carrying value, capitalization and amortization of software and Website development costs, the carrying value of investments, the provision for income taxes and related deferred tax accounts, certain accrued liabilities, revenue recognition, contingencies, litigation and related legal accruals and the value attributed to employee stock options and other stock-based awards. Seasonality The timing of the Company’s revenue is affected by seasonal factors. The Company’s public portal advertising and sponsorship revenue is seasonal, primarily due to the annual spending patterns of the advertising and sponsorship clients of the Company’s public portals. This portion of the Company’s revenue is usually the lowest in the first quarter of each calendar year, and generally increases during each consecutive quarter throughout the year. The timing of revenue in relation to the Company’s expenses, many of which do not vary directly with revenue, has an impact on cost of operations, sales and marketing, and general and administrative expenses as a percentage of revenue in each calendar quarter. Cash and Cash Equivalents All highly liquid investments with an original maturity from the date of purchase of three months or less are considered to be cash equivalents. These investments are stated at cost, which approximates market. The Company’s cash and cash equivalents are generally invested in various money market accounts. Fair Value The carrying amount of cash and cash equivalents, accounts receivable, accrued expenses and deferred revenue is deemed to approximate fair value due to the immediate or short-term maturity of these financial instruments. See Note 12 for further information on the fair value of the Company’s investments. Allowance for Doubtful Accounts The allowance for doubtful accounts receivable reflects the Company’s best estimate of losses inherent in the Company’s receivable portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available evidence. Long-Lived Assets Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets. The useful lives are generally as follows: Computer equipment 3 to 5 years Office equipment, furniture and fixtures 4 to 7 years Software 3 years Building and improvements Up to 40 years Website development costs 3 years Leasehold improvements Shorter of useful life or lease term Expenditures for maintenance, repair and renewals of minor items are charged to expense as incurred. Major improvements are capitalized. Goodwill and Intangible Assets Goodwill and intangible assets result from business combinations accounted for under the acquisition method. Goodwill and other intangible assets with indefinite lives are not amortized and are subjected to impairment review by applying fair value based tests. Intangible assets with definite lives are amortized on a straight-line basis over the individually estimated useful lives of the related assets as follows: Content 3 to 5 years Customer relationships 5 to 12 years Acquired technology and patents 3 years Trade names Up to 10 years Recoverability The Company reviews the carrying value of goodwill and indefinite-lived intangible assets annually and whenever indicators of impairment are present. The Company has one reporting unit and tests goodwill for impairment at the reporting unit level only when, after completing a qualitative analysis, it is determined that it is more likely than not that the fair value of the reporting unit is less than its carrying value. Fair value is determined using an income approach valuation. A reporting unit is defined as an operating segment or one level below an operating segment. Long-lived assets used in operations are reviewed for impairment whenever events or changes in circumstances indicate that carrying amounts may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and the fair value. Long-lived assets held for sale are reported at the lower of cost or fair value less costs to sell. Based on the Company’s analysis, there was no impairment of goodwill or indefinite-lived intangible assets during the years ended December 31, 2015, 2014 and 2013. Internal Use Software Software development costs that are incurred in the preliminary project stage are expensed as incurred. Once certain criteria have been met, direct costs incurred in developing or obtaining computer software are capitalized. The Company capitalized $6,441 and $5,369 during the years ended December 31, 2015 and 2014, respectively. Capitalized internal use software development costs are included in property and equipment in the accompanying consolidated balance sheets. Training and data conversion costs are expensed as incurred. Capitalized software costs are depreciated over a three-year period. Depreciation expense related to internal use software was $6,403, $6,449 and $5,070 for the years ended December 31, 2015, 2014 and 2013, respectively. The remaining balance of internal use software, net of accumulated depreciation, was $11,630 and $11,597 as of December 31, 2015 and 2014, respectively. Website Development Costs Costs related to the planning and post-implementation phases of WebMD’s Website development efforts, as well as minor enhancements and maintenance, are expensed as incurred. Direct costs incurred in the development phase are capitalized. The Company capitalized $4,861 and $5,539 during the years ended December 31, 2015 and 2014, respectively. These capitalized costs are included in property and equipment in the accompanying consolidated balance sheets and are depreciated over a three-year period. Depreciation expense related to Website development costs was $6,580, $6,421 and $5,696 during the years ended December 31, 2015, 2014 and 2013, respectively. The remaining balance of Website development costs, net of accumulated depreciation, was $9,624 and $11,343 as of December 31, 2015 and 2014, respectively. Restricted Cash The Company’s restricted cash primarily relates to collateral for letters of credit obtained to support the Company’s operations. Total restricted cash was $3,547 and $1,765 as of December 31, 2015 and 2014, respectively, and is included in other assets in the accompanying consolidated balance sheets. Deferred Charges Other assets includes costs associated with the issuance of the Company’s convertible notes that are amortized to interest expense in the accompanying consolidated statements of operations, using the effective interest method over the period from issuance through the earliest date on which holders can demand redemption. During the year ended December 31, 2011, the Company capitalized issuance costs of $12,655 and $12,595, related to the issuance of its 2.50% Convertible Notes due 2018 (the “2.50% Notes”) and its 2.25% Convertible Notes due 2016 (the “2.25% Notes”), respectively. Additionally, during the year ended December 31, 2013, the Company capitalized $8,177 of issuance costs in connection with the 2013 issuance of its 1.50% Convertible Notes due 2020 (the “1.50% Notes”). The aggregate amortization of these issuance costs, which is included within interest expense in the accompanying consolidated statements of operations, was $4,172, $4,511 and $4,192 for the years ended December 31, 2015, 2014 and 2013, respectively. During the years ended December 31, 2015 and 2013, the Company wrote off issuance costs of $571 and $2,285, respectively, in connection with the repurchase of a portion of its 2.25% Notes. As of December 31, 2015 and 2014, there were $9,612 and $14,355, respectively, of unamortized issuance costs included in other assets within the accompanying consolidated balance sheets. Deferred Revenue Deferred revenue consists of invoices sent to customers or payments received from customers, in advance of revenue recognition and is recognized as the revenue recognition criteria are met. Deferred revenue is influenced by several factors, including the timing of invoices to our customers and the timing of payments received from our customers in relation to the timing of the revenue recognition for the related customer contract. Deferred revenue at each balance sheet date is expected to be recognized during the succeeding twelve month period and is therefore classified as a current liability within the accompanying consolidated balance sheets. Leases The Company recognizes rent expense on a straight-line basis, including predetermined fixed escalations, over the initial lease term including reasonably assured renewal periods, net of lease incentives, from the time that the Company controls the leased property. Leasehold improvements made at the inception of the lease are amortized over the shorter of the useful life of the asset or the lease term. Lease incentives are recorded as a deferred credit and recognized as a reduction to rent expense on a straight-line basis over the lease term as described above. Presentation of Segment Information The Company generates revenue in four groups, as set forth in the table below. The first group is “Advertising and Sponsorship – Biopharma and Medical Device” and consists of advertising and sponsorship revenue from pharmaceutical, biotechnology and medical device clients relating to ethical pharmaceutical products or other regulated devices or products or for sponsoring educational programs. The second category is “Advertising and Sponsorship – OTC, CPG and Other” and consists of advertising and sponsorship revenue relating to non-Rx or over-the-counter medications and other healthcare products, food and beverages, beauty products and other consumer products, as well as revenue from clients such as retailers, pharmacies, hospitals, health insurance companies and government agencies. The combined revenue of the first two groups is sometimes referred to as “Advertising and Sponsorship” revenue. The third group is “Private Portal Services” and consists of revenue from employers and health plans for subscriptions to the Company’s private portals solution and related services, including health coaching and condition management services. The fourth group is “Information Services” and consists of revenue from the sale of stand-alone information and data products. Discrete financial information related to a measure of profit or loss for these four revenue groups is not available as they leverage many common expenses, and the Company does not separately allocate these common expenses in assessing the performance of its business. Accordingly, the Company views its business as one reportable segment. The following table presents the revenues recognized from the four revenue groups described above: Years Ended December 31, 2015 2014 2013 Advertising and sponsorship Biopharma and medical device $ 371,220 $ 329,329 $ 304,018 OTC, CPG and other 127,805 124,636 113,009 499,025 453,965 417,027 Private portal services 110,441 103,182 82,111 Information services 26,933 23,302 16,155 $ 636,399 $ 580,449 $ 515,293 The Company’s revenue is principally generated in the United States. An adverse change in economic conditions in the United States could negatively affect the Company’s revenue and results of operations. The Company recorded revenue from its international operations of $56,979, $46,095 and $31,340 during the years ended December 31, 2015, 2014 and 2013, respectively. Sales, Use and Value Added Tax The Company excludes sales, use and value-added tax from revenue in the accompanying consolidated statements of operations. Advertising Costs Advertising costs are generally expensed as incurred and totaled $4,359, $4,196 and $5,174 in 2015, 2014 and 2013, respectively. Foreign Currency The functional currency of the Company’s foreign operations is the U.S. dollar. Fluctuations in foreign currency monetary assets and liabilities result in gains or losses which are credited or charged to income. Foreign currency transactional gains or losses are also credited or charged to income. Concentration of Credit Risk None of the Company’s customers individually accounted for more than 10% of the Company’s revenue in 2015, 2014 or 2013 or more than 10% of the Company’s accounts receivable as of December 31, 2015 or 2014. Loss Contingencies The Company accounts for loss contingencies in accordance with Financial Accounting Standards Board (“FASB”) ASC No. 450, “Contingencies.” Under ASC No. 450, accruals for loss contingencies are recorded when both (i) the information available indicates that it is probable that a liability has been incurred and (ii) the amount of the loss can be reasonably estimated. The Company records adjustments to these accruals to reflect the status of negotiations, settlements, advice of counsel and other information and events related to an individual matter. Income Taxes Deferred income taxes are recognized for the future tax consequence of differences between the tax and financial reporting basis of assets and liabilities at each reporting period. A valuation allowance is established to reduce deferred tax assets to the amount expected to be realized. Tax contingencies are recorded to address potential exposure involving tax positions the Company has taken that could be challenged by tax authorities. These potential exposures result from applications of various statutes, rules, regulations and interpretations. The Company’s estimates of tax contingencies contain assumptions and judgments about potential actions by taxing jurisdictions. The Company reflects interest and penalties related to uncertain tax positions as part of the income tax provision in the accompanying consolidated statements of operations. Accounting for Stock-Based Compensation Stock-based compensation expense for all share-based payment awards granted is determined based on the grant-date fair value. The grant-date fair value for stock options is estimated using the Black-Scholes Option Pricing Model. The Company recognizes these compensation costs net of an estimated forfeiture rate on a straight-line basis over the requisite service period of the award, which is generally the vesting term of the share-based Revenue Recognition Revenue from advertising is recognized as advertisements are delivered or as publications are distributed. Revenue from sponsorship arrangements, content syndication and distribution arrangements and subscriptions to healthcare management tools and private portals as well as related health coaching services is recognized ratably over the term of the applicable agreement. Revenue from information services is recognized as the underlying data is delivered. Revenue from the sponsorship of CME is recognized over the period the Company substantially completes its contractual deliverables as determined by the applicable agreements. Contracts that contain multiple deliverables are subject to Accounting Standards Update (“ASU”) No. 2009-13 Pursuant to the guidance of ASU 2009-13, when a sales arrangement contains multiple deliverables, the Company allocates revenue to each deliverable based on relative selling price. The selling price for a deliverable is based on vendor-specific objective evidence (“VSOE”) if available, third-party evidence (“TPE”) if VSOE is not available, or best estimate of selling price if neither VSOE nor TPE is available. The Company then recognizes revenue on each deliverable in accordance with its revenue recognition policies over the period that delivery occurs. VSOE of selling price is based on the price charged when the deliverable is sold separately. In determining VSOE, GAAP requires that a substantial majority of the selling prices fall within a reasonable range based on historical pricing trends for specific products and services. TPE is based on competitor prices of similar deliverables when sold separately. The Company is not able to determine TPE of selling price as it is unable to reliably determine what competitors’ selling prices are for comparable services, combined with the fact that its services often contain unique features and customizations such that comparable services do not exist. The determination of best estimate of selling price is a judgmental process that considers multiple factors including, but not limited to, recent selling prices and related discounting practices for each service, market conditions, customer classes, sales channels and other factors. Net Income Per Common Share Basic income per common share has been computed using the weighted-average number of shares of Common Stock outstanding during the periods presented. Diluted income per common share has been computed using the weighted-average number of shares of Common Stock outstanding during the periods, increased to give effect to potentially dilutive securities and assumes that any dilutive convertible notes were converted, only in the periods in which such effect is dilutive (shares in thousands): Years Ended December 31, 2015 2014 2013 Numerator: Income from continuing operations – Basic $ 64,024 $ 40,941 $ 15,116 Interest expense on 1.50% Notes, net of tax 3,456 3,456 — Interest expense on 2.50% Notes, net of tax 7,189 — — Interest expense on 2.25% Notes, net of tax 3,460 — — Income from continuing operations – Diluted $ 78,129 $ 44,397 $ 15,116 Income from discontinued operations, net of tax – Basic and Diluted $ — $ 1,122 $ — Denominator: Weighted-average shares – Basic 36,600 37,869 46,830 Stock options and restricted stock 1,412 2,060 1,568 1.50% Notes 5,694 5,685 — 2.50% Notes 6,205 — — 2.25% Notes 2,742 — — Adjusted weighted-average shares after assumed conversions – Diluted 52,653 45,614 48,398 Basic income per common share: Income from continuing operations $ 1.75 $ 1.08 $ 0.32 Income from discontinued operations — 0.03 — Net income $ 1.75 $ 1.11 $ 0.32 Diluted income per common share: Income from continuing operations $ 1.48 $ 0.97 $ 0.31 Income from discontinued operations — 0.03 — Net income $ 1.48 $ 1.00 $ 0.31 The Company has excluded certain of its convertible notes, as well as certain outstanding stock options and restricted stock, from the calculation of diluted income per common share during the periods in which such securities were anti-dilutive. The following table presents the total weighted-average number of potentially dilutive common shares that were excluded from the computation of diluted income per common share during the periods presented (shares in thousands): Years Ended December 31, 2015 2014 2013 Options and restricted stock 3,678 2,594 5,744 1.50% Notes — — 556 2.25% Notes — 3,506 5,020 2.50% Notes — 6,195 6,148 3,678 12,295 17,468 Discontinued Operations A business unit is reported as a discontinued operation if its disposal represents a strategic shift that has, or will have, a major effect on the Company’s operations and financial results. Significant judgments are involved in determining whether a business component meets the criteria for discontinued operation reporting and the period in which these criteria are met . Recent Accounting Pronouncements Accounting Pronouncement Adopted During 2015 In April 2014, the FASB issued ASU No. 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity Accounting Pronouncements to be Adopted in the Future In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date In June 2014, the FASB issued ASU No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period In April 2015, the FASB issued ASU No. 2015-03, Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs In April 2015, the FASB issued ASU No. 2015-05, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU No. 2016-01, Leases (Topic 842)

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2015
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	3. Discontinued Operations On October 19, 2009, the Company completed the sale of its Porex business. In connection with the sale of Porex, the Company agreed to indemnify Porex for certain tax matters. As of December 31, 2013, the remaining estimate of the Company’s tax indemnification liability related to Porex was $1,506. During the year ended December 31, 2014, the Company paid $384 in connection with the completion of the remaining tax audits for all periods covered under the indemnity agreement. The remaining indemnity liability of $1,122 was adjusted through income from discontinued operations during the year ended December 31, 2014. The Company has no further obligations related to this matter.

Convertible Notes

Convertible Notes	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Convertible Notes	4. Convertible Notes 2.50% Convertible Notes due 2018 On January 11, 2011, the Company issued $400,000 aggregate principal amount of its 2.50% Notes in a private offering. Unless previously converted, the 2.50% Notes will mature on January 31, 2018. Net proceeds from the sale of the 2.50% Notes were approximately $387,345, after deducting the related offering expenses, of which approximately $100,000 was used to repurchase 1,920,490 shares of the Company’s Common Stock at a price of $52.07 per share, the last reported sale price of the Company’s Common Stock on January 5, 2011, which repurchase settled on January 11, 2011. Interest on the 2.50% Notes is payable semi-annually on January 31 and July 31 of each year, commencing July 31, 2011. Under the terms of the 2.50% Notes, holders were able to surrender their 2.50% Notes for conversion into the Company’s Common Stock at an initial conversion rate of 15.1220 shares of Common Stock per thousand dollars principal amount of the 2.50% Notes. This was equivalent to an initial conversion price of approximately $66.13 per share of Common Stock. In the aggregate, the 2.50% Notes were convertible into 6,048,800 shares of the Company’s Common Stock. Effective April 4, 2012, after giving effect to an adjustment resulting from a tender offer for the Company’s Common Stock that the Company completed on April 3, 2012, the conversion rate was adjusted to 15.3223 shares of Common Stock per thousand dollars principal amount of the 2.50% Notes. This was equivalent to an adjusted conversion price of approximately $65.26 per share of Common Stock. In the aggregate, the 2.50% Notes were convertible into 6,128,920 shares of Common Stock following the April 4, 2012 adjustment. Effective September 11, 2013, after giving effect to an adjustment resulting from a tender offer for the Company’s Common Stock that the Company completed on September 10, 2013 (see Note 10 for additional discussion), the conversion rate was adjusted to 15.4764 shares of Common Stock per thousand dollars principal amount of the 2.50% Notes. This was equivalent to an adjusted conversion price of approximately $64.61 per share of Common Stock. In the aggregate, the 2.50% Notes were convertible into 6,190,560 shares of Common Stock following the September 11, 2013 adjustment. Effective September 10, 2014, after giving effect to an adjustment resulting from a tender offer for the Company’s Common Stock that the Company completed on September 9, 2014 (see Note 10 for additional discussion), the conversion rate was adjusted to 15.5118 shares of Common Stock per thousand dollars principal amount of the 2.50% Notes. This is equivalent to an adjusted conversion price of approximately $64.47 per share of Common Stock. In the aggregate, the 2.50% Notes are convertible into 6,204,720 shares of Common Stock following the September 10, 2014 adjustment. Under the terms of the 2.50% Notes, if the Company undergoes certain change of control transactions prior to the maturity date of the 2.50% Notes, holders of the 2.50% Notes will have the right, at their option, to require the Company to repurchase some or all of their 2.50% Notes at a repurchase price equal to 100% of the principal amount of the 2.50% Notes being repurchased, plus accrued and unpaid interest to, but excluding, the repurchase date. At the Company’s option, and to the extent permitted by the applicable rules of the Nasdaq Global Select Market (or the applicable rules of such other exchange on which the Company’s Common Stock may be listed), instead of paying the repurchase price in cash, the Company may pay the repurchase price in shares of its Common Stock or a combination of cash and shares of its Common Stock. However, in the case of certain change of control transactions in which the Company is acquired by a public company, the Company may elect to provide for conversion of the 2.50% Notes into acquirer common stock, in which case the repurchase option would not apply. 2.25% Convertible Notes due 2016 On March 14, 2011, the Company issued $400,000 aggregate principal amount of its 2.25% Notes in a private offering. Unless previously converted, the 2.25% Notes will mature on March 31, 2016. Net proceeds from the sale of the 2.25% Notes were approximately $387,400, after deducting the related offering expenses, of which approximately $50,000 was used to repurchase 868,507 shares of the Company’s Common Stock at a price of $57.57 per share, the last reported sale price of the Company’s Common Stock on March 8, 2011, which repurchase settled on March 14, 2011. Interest on the 2.25% Notes is payable semi-annually on March 31 and September 30 of each year, commencing September 30, 2011. Under the terms of the 2.25% Notes, holders were able to surrender their 2.25% Notes for conversion into the Company’s Common Stock at an initial conversion rate of 13.5704 shares of Common Stock per thousand dollars principal amount of the 2.25% Notes. This was equivalent to an initial conversion price of approximately $73.69 per share of Common Stock. In the aggregate, the 2.25% Notes were convertible into 5,428,160 shares of the Company’s Common Stock. Effective April 4, 2012, after giving effect to an adjustment resulting from a tender offer for the Company’s Common Stock that the Company completed on April 3, 2012, the conversion rate was adjusted to 13.7502 shares of Common Stock per thousand dollars principal amount of the 2.25% Notes. This was equivalent to an adjusted conversion price of approximately $72.73 per share of Common Stock. In the aggregate, the 2.25% Notes are convertible into 5,500,080 shares of Common Stock following the April 4, 2012 adjustment. Effective September 11, 2013, after giving effect to an adjustment resulting from a tender offer for the Company’s Common Stock that the Company completed on September 10, 2013 (see Note 10 for additional discussion), the conversion rate was adjusted to 13.8884 shares of Common Stock per thousand dollars principal amount of the 2.25% Notes. This was equivalent to an adjusted conversion price of approximately $72.00 per share of Common Stock. In the aggregate, the 2.25% Notes were convertible into 5,555,360 shares of Common Stock following the September 11, 2013 adjustment. During the year ended December 31, 2013, the Company repurchased $100,000 principal amount of its 2.25% Notes for $101,750 in cash in a privately negotiated transaction. Also during the year ended December 31, 2013, the Company repurchased $47,768 principal amount of its 2.25% Notes for $48,604 in cash in the open market. The Company recognized a pre-tax loss of $4,871 in 2013 related to these repurchases, which is reflected within loss on convertible notes in the accompanying consolidated statement of operations. The loss included the expensing of the remaining deferred issuance costs outstanding related to the repurchased notes. After these repurchases in 2013, the remaining principal amount of the 2.25% Notes outstanding was $252,232, which, in the aggregate, was convertible into 3,503,099 shares of Common Stock. Effective September 10, 2014, after giving effect to an adjustment resulting from a tender offer for the Company’s Common Stock that the Company completed on September 9, 2014 (see Note 10 for additional discussion), the conversion rate was adjusted to 13.9202 shares of Common Stock per thousand dollars principal amount of the 2.25% Notes. This is equivalent to an adjusted conversion price of approximately $71.84 per share of Common Stock. In the aggregate, the 2.25% Notes were convertible into 3,511,120 shares of Common Stock following the September 10, 2014 adjustment. During the year ended December 31, 2015, the Company repurchased $149,550 principal amount of its 2.25% Notes for $151,038 in cash in privately negotiated transactions. The Company recognized a pre-tax loss of $2,058 in 2015 related to these repurchases, which is reflected within loss on convertible notes in the accompanying consolidated statement of operations. The loss included the expensing of the remaining deferred issuance costs outstanding related to the repurchased notes. After these repurchases, the remaining principal amount of the 2.25% Notes outstanding was $102,682, which, in the aggregate, is convertible into 1,429,354 shares of Common Stock. Under the terms of the 2.25% Notes, if the Company undergoes certain change of control transactions prior to the maturity date of the 2.25% Notes, holders of the 2.25% Notes will have the right, at their option, to require the Company to repurchase some or all of their 2.25% Notes at a repurchase price equal to 100% of the principal amount of the 2.25% Notes being repurchased, plus accrued and unpaid interest to, but excluding, the repurchase date. At the Company’s option, and to the extent permitted by the applicable rules of the Nasdaq Global Select Market (or the applicable rules of such other exchange on which the Company’s Common Stock may be listed), instead of paying the repurchase price in cash, the Company may pay the repurchase price in shares of its Common Stock or a combination of cash and shares of its Common Stock. However, in the case of certain change of control transactions in which the Company is acquired by a public company, the Company may elect to provide for conversion of the 2.25% Notes into acquirer common stock, in which case the repurchase option would not apply. 1.50% Convertible Notes due 2020 On November 26, 2013, the Company issued $300,000 aggregate principal amount of its 1.50% Notes in a private offering. Unless previously converted, the 1.50% Notes will mature on December 1, 2020. Net proceeds from the sale of the 1.50% Notes were approximately $291,823, after deducting the related offering expenses. Interest on the 1.50% Notes is payable semi-annually on June 1 and December 1 of each year, commencing June 1, 2014. Under the terms of the 1.50% Notes, holders were able to surrender their 1.50% Notes for conversion into the Company’s Common Stock at an initial conversion rate of 18.9362 shares of Common Stock per thousand dollars principal amount of the 1.50% Notes. This was equivalent to an initial conversion price of approximately $52.81 per share of Common Stock. In the aggregate, the 1.50% Notes were convertible into 5,680,860 shares of the Company’s Common Stock. The conversion rate may be adjusted under certain circumstances. Effective September 10, 2014, after giving effect to an adjustment resulting from a tender offer for the Company’s Common Stock that the Company completed on September 9, 2014 (see Note 10 for additional discussion), the conversion rate was adjusted to 18.9795 shares of Common Stock per thousand dollars principal amount of the 1.50% Notes. This is equivalent to an adjusted conversion price of approximately $52.69 per share of Common Stock. In the aggregate, the 1.50% Notes are convertible into 5,693,850 shares of Common Stock following the September 10, 2014 adjustment. Under the terms of the 1.50% Notes, if the Company undergoes certain change of control or other fundamental change transactions prior to the maturity date of the 1.50% Notes, holders of the 1.50% Notes will have the right, at their option, to require the Company to repurchase some or all of their 1.50% Notes at a repurchase price equal to 100% of the principal amount of the 1.50% Notes being repurchased, plus accrued and unpaid interest to, but excluding, the repurchase date. However, the repurchase option will not apply in the case of certain change of control or other fundamental change transactions in which the Company is acquired by a public company, and (a) not less than 90% of the consideration received or to be received by holders of WebMD Common Stock, excluding cash payments for fractional shares, consists of acquirer common stock and (b) as a result of the transaction, the 1.50% Notes become convertible into the same consideration.

Long-Lived Assets

Long-Lived Assets	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Long-Lived Assets	5. Long-Lived Assets Property and Equipment Property and equipment consist of the following: December 31, 2015 2014 Software $ 66,708 $ 60,341 Computer equipment 69,973 63,541 Web site development costs 62,784 57,922 Leasehold improvements 72,679 44,000 Office equipment, furniture and fixtures 17,398 15,154 Land and buildings 291 291 289,833 241,249 Less: accumulated depreciation (208,806 ) (181,676 ) Property and equipment, net $ 81,027 $ 59,573 Depreciation expense was $27,200, $27,010 and $24,335 in 2015, 2014 and 2013, respectively. Goodwill and Intangible Assets The balance of goodwill was $202,980 as of December 31, 2015 and 2014. Intangible assets consist of the following: December 31, 2015 December 31, 2014 Weighted Weighted Gross Average Gross Average Carrying Accumulated Remaining Carrying Accumulated Remaining Amount Amortization Net Useful Life (a) Amount Amortization Net Useful Life (a) Content $ 15,954 $ (15,954 ) $ — — $ 15,954 $ (15,954 ) $ — — Customer relationships 34,057 (29,218 ) 4,839 2.7 34,057 (27,126 ) 6,931 3.6 Technology and patents 17,882 (16,291 ) 1,591 1.5 17,882 (15,231 ) 2,651 2.5 Trade names-definite lives 2,530 (2,530 ) — — 2,530 (2,361 ) 169 1.0 Trade names-indefinite lives 4,464 — 4,464 n/a 4,464 — 4,464 n/a Total $ 74,887 $ (63,993 ) $ 10,894 $ 74,887 $ (60,672 ) $ 14,215 (a) The calculation of the weighted average remaining useful life is based on the net book value and the remaining amortization period of each respective intangible asset. In July 2014, the Company acquired the assets of TheraSim, Inc. for $3,182 in cash. TheraSim’s technology provides the content and programming for certain of the Company’s sponsorship services. The purchase price was allocated to an intangible asset, “Technology,” is being amortized over a 3-year term and is included within “Technology and Patents” in the above table. Amortization expense was $3,321, $2,801 and $2,271 in 2015, 2014 and 2013, respectively. Future amortization expense for intangible assets is estimated to be: Year Ending December 31: 2016 $ 3,120 2017 $ 2,044 2018 $ 1,266

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Accrued Expenses	6. Accrued Expenses Accrued expenses consist of the following: December 31, 2015 2014 Accrued compensation $ 45,715 $ 38,856 Accrued outside services 10,775 11,089 Accrued marketing and distribution 5,383 4,442 Accrued interest 5,119 5,960 Other accrued liabilities 13,672 12,311 $ 80,664 $ 72,658

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. Commitments and Contingencies Legal Proceedings and Claims Dual Diagnosis Treatment Center, et al. v. Blue Cross of California, et al. On May 8, 2015, six providers of substance abuse and/or mental health treatment services located in the States of California, Arizona and Florida filed an action in the United States District Court for the Central District of California initially against twenty-eight (28) Blue Cross and Blue Shield companies (collectively “Blue Cross”), as well as at least forty-one (41) health and benefit plans, including the WebMD Health and Welfare Plan (the “Health Plan”). Additional defendants have since been added. Horizon Blue Cross Blue Shield of New Jersey, one of the Blue Cross companies named as a defendant, serves as third-party claims administrator for the Health Plan, a welfare plan sponsored by the Company under the applicable provisions of the Employee Retirement Income Security Act of 1974 (“ERISA”). The Company self-insures (up to the deductible amount under the Company’s stop loss insurance policy) the group health plan component of the Health Plan. The Company serves as “plan administrator” for the Health Plan under ERISA. The plaintiffs, “out-of-network” providers to Blue Cross, claim that Blue Cross improperly ignored assignments of benefits received by the plaintiffs from the individual plan participants and sent payments directly to such individual participants who then failed to remit those payments to the providers. Plaintiffs claim that defendants’ failures to honor the assignments violate ERISA and state law and they seek recovery for benefit claims in unspecified amounts that they claim have been paid to the wrong party together with attorney fees, as well as removal of all fiduciaries who are found to have breached ERISA-imposed duties under the relevant health and benefit plans on account of such conduct, and injunctive relief to enjoin Blue Cross from alleged unlawful practices regarding assignments of benefits. The Company has not yet filed an answer to the complaint. On September 14, 2015, the defendants in the case, including the Company, filed a motion to dismiss the complaint for failure to state a claim. Thereafter, the plaintiffs amended the complaint and added new parties. The Company received an extension of its time to respond to the amended complaint and on January 25, 2016, renewed its motion to dismiss after all new parties were served and appeared in the case. The Company is unable to predict the outcome of this action or to reasonably estimate the possible loss or range of loss, if any, arising from the claims asserted therein. Other Legal Proceedings and Claims In the normal course of business, the Company and its subsidiaries are involved in various claims and legal proceedings. While the ultimate resolution of these matters has yet to be determined, the Company does not believe that their outcomes will have a material adverse effect on the Company’s consolidated financial position, results of operations or liquidity. Leases The Company leases its offices and other facilities under operating lease agreements that expire at various dates through 2024. Total rent expense for all operating leases was approximately $6,506, $9,194 and $8,805 in 2015, 2014 and 2013, respectively. Included in other long-term liabilities as of December 31, 2015 and 2014 were $12,071 and $10,605, respectively, related to lease incentives and the difference between rent expense and the rental amount payable for leases with fixed escalations. Future minimum lease commitments under non-cancelable lease agreements at December 31, 2015 were as follows: Year Ending December 31: 2016 $ 14,773 2017 15,122 2018 14,826 2019 14,035 2020 14,414 Thereafter 33,697 Total minimum lease payments $ 106,867 Other Contingencies The Company provides certain indemnification provisions within its customer agreements to protect the other party from any liabilities or damages resulting from a claim of misappropriation or infringement by third parties relating to its products and services. The Company has not incurred a liability relating to any of these indemnification provisions in the past and management believes that the likelihood of any future payment relating to these provisions is unlikely. Therefore, the Company has not recorded a liability during any period for these indemnification provisions.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	8. Stock-Based Compensation The Company has various stock-based compensation plans (collectively, the “Plans”) that provide for the grant of stock options, restricted stock, and other awards based on WebMD Common Stock. The 2005 Long-Term Incentive Plan (as amended, the “2005 Plan”) is the only existing plan under which future grants can be made. The maximum number of shares of the Company’s Common Stock that may be subject to awards under the 2005 Plan was 24,975,000 as of December 31, 2015, subject to adjustment in accordance with the terms of the 2005 Plan. The Company had an aggregate of 2,320,338 shares of Common Stock available for future grants under the 2005 Plan at December 31, 2015. Stock Options Generally, options under the Plans vest and become exercisable ratably over periods ranging from two to five years based on their individual grant dates, subject to continued employment on the applicable vesting dates, and generally expire within ten years from the date of grant. Options are granted at prices not less than the fair market value of the Company’s Common Stock on the date of grant. The following table summarizes stock option activity for the Plans: Shares Weighted Weighted Aggregate (a) Outstanding at January 1, 2013 13,300,688 $ 26.24 Granted 2,844,500 33.64 Exercised (2,695,600 ) 20.90 Cancelled (2,020,309 ) 27.50 Outstanding at December 31, 2013 11,429,279 29.12 Granted 899,200 43.03 Exercised (3,875,410 ) 24.40 Cancelled (905,543 ) 33.42 Outstanding at December 31, 2014 7,547,526 32.69 Granted 2,134,900 42.75 Exercised (989,993 ) 24.53 Cancelled (821,998 ) 38.68 Outstanding at December 31, 2015 7,870,435 $ 35.81 6.7 $ 99,384 Vested and exercisable at the end of the period 4,101,045 $ 32.22 5.1 $ 67,010 (a) The aggregate intrinsic value is based on the market price of the Company’s Common Stock on December 31, 2015, which was $48.30, less the applicable exercise price of the underlying option. This aggregate intrinsic value represents the amount that would have been realized if all the option holders had exercised their options on December 31, 2015. The following table summarizes information with respect to options outstanding and options exercisable at December 31, 2015: Outstanding Exercisable Exercise Prices Shares Weighted Weighted Shares Weighted $13.15 - $19.95 532,595 $ 13.50 6.9 465,720 $ 13.31 $20.21 - $25.99 636,867 22.78 4.4 497,217 22.80 $26.03 - $29.92 838,411 28.08 4.0 791,961 28.07 $30.00 - $33.40 1,037,794 32.15 6.8 703,044 31.64 $33.55 - $38.60 658,575 36.73 5.9 465,187 36.85 $38.65 - $39.50 1,019,918 39.07 7.9 326,258 39.05 $39.51 - $42.98 531,500 40.56 6.8 170,500 40.84 $42.99 1,336,000 42.99 9.2 — — $43.05 - $46.46 637,000 44.72 8.3 134,200 45.46 $46.50 - $58.96 641,775 49.46 4.7 546,958 49.70 7,870,435 $ 35.81 6.7 4,101,045 $ 32.22 The fair value of each option granted is estimated on the date of grant using the Black-Scholes option pricing model considering the weighted-average assumptions noted in the following table. Expected volatility is based on implied volatility from traded options of the Company’s Common Stock combined with historical volatility of the Company’s Common Stock. The expected term represents the period of time that options are expected to be outstanding following their grant date, and was determined using historical exercise data combined with assumptions for future exercise activity. The risk-free rate is based on the U.S. Treasury yield curve for periods equal to the expected term of the options on the grant date. Years Ended December 31, 2015 2014 2013 Expected dividend yield 0.0 % 0.0 % 0.0 % Expected volatility 0.41 - 0.48 0.47 - 0.49 0.43 - 0.48 Risk-free interest rate 1.01% - 1.56 % 1.16% - 1.72 % 0.55% - 1.62 % Expected term (years) 4.1 - 4.7 4.2 - 5.0 4.5 - 5.1 Weighted-average fair value of options granted during the period $ 16.26 $ 17.58 $ 13.95 Restricted Stock The Company’s Restricted Stock consists of shares of the Company’s Common Stock which have been awarded to employees with restrictions that cause them to be subject to substantial risk of forfeiture and restrict their sale or other transfer by the employee until they vest. Generally, the Company’s Restricted Stock grants vest ratably over periods ranging from three to four years from their individual award dates subject to continued employment on the applicable vesting dates. The following table summarizes the activity of the Company’s Restricted Stock: Years Ended December 31, 2015 2014 2013 Shares Weighted Shares Weighted Shares Weighted Balance at beginning of the year 904,083 $ 35.58 1,184,961 $ 33.07 932,386 $ 31.69 Granted 441,920 42.96 177,200 43.84 812,000 32.65 Vested (331,558 ) 35.72 (324,453 ) 32.70 (401,825 ) 32.57 Forfeited (159,600 ) 36.57 (133,625 ) 31.29 (157,600 ) 24.02 Balance at the end of the year 854,845 $ 39.17 904,083 $ 35.58 1,184,961 $ 33.07 Proceeds received from the exercise of options to purchase shares of the Company’s Common Stock were $21,939, $40,602 and $29,724 for the years ended December 31, 2015, 2014 and 2013, respectively. Additionally, in connection with the exercise of certain stock options and the vesting of restricted stock, the Company made payments of $6,438, $33,385 and $12,526 during the years ended December 31, 2015, 2014 and 2013, respectively, related to employee statutory withholding taxes that were satisfied by withholding shares of Common Stock of equal value from the respective employees. The proceeds and payments described above are reflected within cash flows from financing activities within the accompanying consolidated statements of cash flows. The intrinsic value related to stock options that were exercised, combined with the fair value of shares of restricted stock that vested, aggregated $34,670, $100,232 and $45,882 for the years ended December 31, 2015, 2014 and 2013, respectively. Other Each year the Company issues shares of its Common Stock to WebMD non-employee directors with a value equal to their annual board and committee retainers. The Company recorded $467, $315 and $364 of stock-based compensation expense for the years ended December 31, 2015, 2014 and 2013, respectively, in connection with these issuances. Summary of Stock-Based Compensation Expense The following table summarizes the components and classification of stock-based compensation expense: Years Ended December 31, 2015 2014 2013 Stock options $ 21,336 $ 21,117 $ 24,483 Restricted stock 11,940 11,114 13,703 Other 467 315 364 Total stock-based compensation expense $ 33,743 $ 32,546 $ 38,550 Included in: Cost of operations $ 5,217 $ 5,940 $ 6,762 Sales and marketing 7,290 7,221 8,395 General and administrative 21,236 19,385 23,393 Total stock-based compensation expense $ 33,743 $ 32,546 $ 38,550 As of December 31, 2015, approximately $56,930 of unrecognized stock-based compensation expense related to unvested awards (net of estimated forfeitures) is expected to be recognized over a weighted-average period of approximately 2.3 years, related to the Plans. Tax benefits attributable to stock-based compensation represented approximately 38% of stock-based compensation expense during the year ended December 31, 2015 and 39% of stock-based compensation expense during each of the years ended December 31, 2014 and 2013.

Retirement Plans

Retirement Plans	12 Months Ended
	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Retirement Plans	9. Retirement Plans The Company maintains certain defined contribution retirement plans covering substantially all of its employees, which provide for matching and discretionary contributions. The Company has recorded expenses related to these plans of $4,495, $3,971 and $3,903 for 2015, 2014 and 2013, respectively, related to these matching and discretionary contributions.

Equity

Equity	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Equity	10. Equity Treasury Stock Repurchased shares are recorded under the cost method and are reflected as treasury stock in the accompanying consolidated balance sheets, unless the shares are cancelled and retired. Tender Offers On September 9, 2014, the Company completed a tender offer (the “2014 Tender Offer”) through which it repurchased 2,000,000 shares of its Common Stock at a price of $48.50 per share for total consideration of $97,588, which includes $588 of costs directly attributable to the purchase. The shares repurchased through the 2014 Tender Offer are reflected as treasury stock in the accompanying consolidated balance sheets. On September 10, 2013, the Company completed a tender offer (the “2013 Tender Offer”) through which it repurchased 5,000,000 shares of its Common Stock at a price of $34.00 per share for total consideration of $170,516, which includes $516 of costs directly attributable to the purchase. The shares repurchased through the 2013 Tender Offer were cancelled and retired. Stock Repurchase Program In August 2011, the Board of Directors established a stock repurchase program (the “Program”) through which the Company was authorized to use up to $75,000 to purchase shares of WebMD Common Stock, from time to time, in the open market, through block trades or in private transactions, depending on market conditions and other factors. In October 2011, February 2014, March 2014, April 2014, November 2014 and September 2015, the Company’s Board of Directors authorized increases to the Program of $75,000, $50,000, $40,000, $30,000, $23,895 and $27,451, respectively. During 2013, the Company repurchased 1,266,962 shares at an aggregate cost of $42,309 under the Program. During 2014, the Company repurchased 3,160,070 shares at an aggregate cost of $128,748 under the Program. During 2015, the Company repurchased 688,467 shares at an aggregate cost of $28,406 under the Program. The Company paid cash of $569 in 2013 related to the repurchase of 39,857 shares in 2012, that settled in 2013. As of December 31, 2015, $34,056 remained available for repurchases under the Program. Other Repurchase Activity On October 21, 2013, the Company repurchased 5,527,433 shares of its Common Stock that were beneficially owned by Carl C. Icahn and certain of his affiliates, at a purchase price of $32.08 per share, the NASDAQ official closing price of WebMD Common Stock on October 18, 2013. The total purchase price was $177,420, which includes $100 of costs directly attributable to the purchase. This share repurchase was not made under the Program. Shareholder Rights Agreement The Board of Directors of the Company adopted, and the Company entered into, a Stockholder Rights Agreement, dated as of November 2, 2011 (the “Rights Agreement”), by and between the Company and American Stock Transfer & Trust Company, LLC, as Rights Agent. Pursuant to the terms of the Rights Agreement, which had a one-year term until amended (as described below), one preferred stock purchase right (a “Right”) was attached to each outstanding share of the Company’s Common Stock held by holders of record as of the close of business on November 14, 2011. The Company issued one Right with each new share of Common Stock issued after that date until the Rights expired. The Rights initially traded with and were inseparable from the Company’s Common Stock and were not evidenced by separate certificates unless they became exercisable. The Rights would, if they had become exercisable, have caused substantial dilution to a person or group that attempted to acquire the Company on terms not approved by the Company’s Board of Directors. However, the Rights would not have interfered with a merger or other business combination approved by the Company’s Board of Directors. Until amended (as described below), each Right entitled its holder to purchase from the Company one one-thousandth of a share (a “Unit”) of Series A Junior Preferred Stock, par value $0.01 per share (the “Preferred Stock”), at an exercise price of $153.00 per Unit, subject to adjustment in accordance with the terms of the Rights Agreement, once the Rights become exercisable. On October 18, 2012, the Board of Directors of the Company adopted, and the Company entered into, an Amendment to Rights Agreement (the “First Amendment”). The First Amendment: extended the expiration date of the Rights Agreement from October 31, 2012 to October 31, 2014; provided that equity compensation awards to directors would not be included in determining whether a stockholder became an “Acquiring Person” under the Rights Agreement; and decreased the purchase price payable by holders of Rights upon exercise of such Rights from $153.00 per Unit to $66.29 per Unit. On August 1, 2013 the Company entered into a Second Amendment to the Rights Agreement (the “Second Amendment”). Pursuant to the Second Amendment, the final expiration date of the Rights Agreement occurred on August 1, 2013, which terminated the Rights Agreement and caused the Rights issued to WebMD stockholders pursuant to the Rights Agreement to expire at the close of business on that date. Accumulated Other Comprehensive Income Accumulated other comprehensive income in the accompanying consolidated balance sheets as of December 31, 2015 and 2014 represents the unrealized gain on available-for-sale securities, net of taxes, related to an equity investment in a publicly traded company that completed its initial public offering in December 2014.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets (liabilities) were as follows: December 31, 2015 2014 Deferred tax assets: Federal net operating loss carryforwards $ 83,071 $ 91,000 State net operating loss carryforwards 33,320 35,488 Capital losses 292 458 Federal tax credits 28,555 56,096 Accrued expenses 19,086 17,919 Stock-based compensation 24,294 21,031 Intangible assets 3,610 3,570 Other 3,808 3,841 Total deferred tax assets 196,036 229,403 Valuation allowance (142,604 ) (157,644 ) Net deferred tax assets 53,432 71,759 Deferred tax liabilities: Property and equipment (1,466 ) (3,063 ) Goodwill and indefinite-lived intangible asset (33,465 ) (30,975 ) Other (2,807 ) (627 ) Total deferred tax liabilities (37,738 ) (34,665 ) Net deferred tax assets $ 15,694 $ 37,094 December 31, 2015 2014 Current deferred tax assets, net: Current deferred tax assets, net of deferred tax liabilities $ 66,665 $ 59,371 Valuation allowance (50,539 ) (41,224 ) Current deferred tax assets, net 16,126 18,147 Non-current deferred tax (liabilities) assets, net: Non-current deferred tax assets, net of deferred tax liabilities 91,633 135,367 Valuation allowance (92,065 ) (116,420 ) Non-current deferred tax (liabilities) assets, net (432 ) 18,947 Net deferred tax assets $ 15,694 $ 37,094 The income tax provision was as follows: Years Ended December 31, 2015 2014 2013 Current: Federal $ 1,076 $ (622 ) $ (73 ) State 4,773 3,047 502 Foreign 268 369 141 Current income tax provision 6,117 2,794 570 Deferred: Federal (8,456 ) 12,570 10,683 State 743 2,147 2,387 Deferred income tax (benefit) provision (7,713 ) 14,717 13,070 Reversal of valuation allowance applied to additional paid-in capital 37,443 13,196 — Total income tax provision $ 35,847 $ 30,707 $ 13,640 The reconciliation between the federal statutory rate and the effective income tax rate is as follows: Years Ended December 31, 2015 2014 2013 United States federal statutory rate 35.0% 35.0% 35.0% State income taxes (net of federal benefit) 5.7 7.4 12.5 Valuation allowance (7.1) (3.3) (6.4) Non-deductible officer compensation 1.4 2.2 3.6 Other 0.9 1.6 2.7 Effective income tax rate 35.9% 42.9% 47.4% During 2015 and 2014, the Company reversed $37,443 and $13,196, respectively, of its valuation allowance through additional paid-in capital as a result of the utilization of net operating loss carryforwards generated by excess tax benefits of share-based payments. In the quarter ended June 30, 2015, the Company increased its valuation allowance by $24,775 for a correcting adjustment related to the realization of excess tax benefits of share-based payments during the years ended December 31, 2011 and 2010, offset by a reversal of a valuation allowance originally recorded during the year ended December 31, 2012. During 2015, 2014 and 2013, the Company reversed $1,455, $1,311 and $1,351, respectively, of its deferred tax asset and related valuation allowance through the tax provision as a result of the expiration of state net operating loss carryforwards, and during 2014, the Company also reversed $1,359 of its deferred tax asset and related valuation allowance through additional paid-in capital as a result of the expiration of state net operating loss carryforwards generated by excess tax benefits of share-based payments. The valuation allowance for deferred tax assets decreased by $15,040 and $16,948 in 2015 and 2014, respectively. At December 31, 2015, the Company had net operating loss carryforwards for federal income tax purposes of approximately $615,000, of which primarily all expire in 2021 through 2034, and federal tax credits of $66,767, which excludes the impact of any unrecognized tax benefits, of which $44,128 expire in 2017 through 2031 and $22,639 can be carried forward indefinitely. The Company uses the “with-and-without” approach in determining the order in which tax attributes are utilized. Using the “with-and-without” approach, the Company will only recognize a tax benefit from share-based The net operating loss carryforwards that are presented on a tax effected basis within the deferred tax assets include approximately $230,000 of gross excess tax benefits related to share-based payments. Since this amount was recorded through additional paid-in capital, the related valuation allowance on these net operating loss carryforwards will be reversed through additional paid-in capital when these excess tax benefits are realized. The net operating loss carryforwards also include gross excess tax benefits related to share-based payments of approximately $460,000 that are not recognized as a deferred tax asset as the amounts would not have resulted in a reduction in current taxes payable if all other tax attributes currently available to the Company were utilized. The benefit of these deductions will be recognized through additional paid-in capital at the time the tax deduction results in a reduction of current taxes payable. The tender offer completed on November 25, 2008 resulted in a cumulative change of more than 50% of the ownership of the Company’s capital, as determined under rules prescribed by the U.S. Internal Revenue Code and applicable Treasury regulations. As a result of the ownership change, there is an annual limitation imposed on the Company’s net operating loss carryforwards and federal tax credits. The Company experienced another cumulative change on February 25, 2011. Despite this second ownership change, the Company’s net operating loss carryforwards and federal tax credits continue to be limited by the November 25, 2008 annual limitation. As of December 31, 2015 and 2014, the Company had unrecognized income tax benefits of $14,815 and $13,553, respectively, of which $14,815 and $8,828, respectively, would result in an income tax benefit if realized. Included in the unrecognized income tax benefits as of December 31, 2015 and 2014 are accrued interest and penalties of $738 and $581, respectively. The Company recognizes interest and penalties related to unrecognized tax benefits as part of the income tax provision. The following table summarizes the activity of unrecognized tax benefits, excluding accrued interest and penalties, for the years ended December 31, 2015, 2014 and 2013: Years Ended December 31, 2015 2014 2013 Balance at the beginning of the year $ 12,972 $ 13,392 $ 13,949 Increases related to prior year tax positions 776 15 — Increases related to current year tax positions 394 — — Decreases related to prior year tax positions — (379 ) (532 ) Settlements (15 ) — — Expiration of the statute of limitations for the assessment of taxes (50 ) (56 ) (25 ) Balance at the end of the year $ 14,077 $ 12,972 $ 13,392 Although the Company files U.S. federal and various state and other tax returns, the major taxing jurisdiction is the U.S. The Company is currently under audit in a number of state and local taxing jurisdictions and will have statutes of limitations with respect to certain tax returns expiring within the next twelve months. As a result, it is reasonably possible that there may be a reduction in the unrecognized income tax benefits, prior to any annual increase, in the range of $100 to $200 within the next twelve months. With the exception of adjusting net operating loss carryforwards that may be utilized, the Company is no longer subject to federal income tax examinations for tax years before 2012 and for state and local income tax examinations for tax years before 2011.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	12. Fair Value of Financial Instruments The Company accounts for certain assets and liabilities at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, the Company uses valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions. The Company did not have any Level 2 or Level 3 assets during the years ended December 31, 2015, 2014 and 2013. The following table sets forth the Company’s Level 1 financial assets that were measured and recorded at fair value on a recurring basis as of December 31, 2015 and 2014: Fair Value Estimate Using: December 31, 2015 December 31, 2014 Amortized Cost Basis Fair Value Gross Unrealized Gains Amortized Cost Basis Fair Value Gross Unrealized Gains Cash and cash equivalents Level 1 $ 641,165 $ 641,165 $ — $ 706,776 $ 706,776 $ — Available-for-sale security Level 1 — 598 598 — 1,603 1,603 The Company’s available-for-sale security consists of an equity investment in a publicly traded company that completed its initial public offering in December 2014. The following table reconciles the beginning and ending balances of the Company’s available-for-sale security during the year ended December 31, 2015: Year Ended Fair value as of the beginning of the period $ 1,603 Cash proceeds received (139 ) Gain included in earnings 139 Change in unrealized gains included in other comprehensive income (1,005 ) Fair value as of the end of the period $ 598 During 2015, the Company recorded a gain on investments of $139, which represents the proceeds received by the Company when it sold a portion of its available-for-sale security. The unrealized gain related to this investment, net of tax, is included within accumulated other comprehensive income in the accompanying consolidated balance sheets as of December 31, 2015 and 2014. The Company also holds an investment in a privately held company which is carried at cost, and not subject to fair value measurements. However, if events or circumstances indicate that its carrying amount may not be recoverable, it would be reviewed for impairment. The Company made this investment in November 2008 by acquiring preferred stock. During November 2014, this investment was converted into a combination of preferred stock and debt securities of another privately held company through an acquisition. The total amount of the Company’s investment in this privately held company is $6,471. Since the Company does not have the ability to exercise significant influence over this company, the investment is accounted for under the cost method and it is included in other assets on the accompanying consolidated balance sheets as of December 31, 2015 and 2014. For disclosure purposes, the Company is required to measure the outstanding value of its debt on a recurring basis. The following table presents the carrying value and estimated fair value (based on Level 1 market price data) of the Company’s convertible notes that were carried at historical cost as of December 31, 2015 and 2014: December 31, 2015 December 31, 2014 Carrying Fair Value Carrying Fair Value 2.25% Notes $ 102,682 $ 102,618 $ 252,232 $ 254,754 2.50% Notes $ 400,000 $ 416,000 $ 400,000 $ 399,000 1.50% Notes $ 300,000 $ 340,566 $ 300,000 $ 299,250

Other Expense

Other Expense	12 Months Ended
	Dec. 31, 2015
Other Income and Expenses [Abstract]
Other Expense	13. Other expense For 2015, other expense represents a charge related to the resolution of a patent infringement claim made by International Business Machines Corporation against the Company. For 2013, other expense consisted of cash severance and related expenses due to the May 2013 departure of a Chief Executive Officer of the Company.

Supplemental Disclosures of Cas

Supplemental Disclosures of Cash Flow Information	12 Months Ended
	Dec. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Supplemental Disclosures of Cash Flow Information	14. Supplemental Disclosures of Cash Flow Information Supplemental information related to the consolidated statements of cash flows is summarized below: Years Ended December 31, 2015 2014 2013 Supplemental Disclosure of Cash Flow Information: Interest paid $ 19,792 $ 20,225 $ 19,038 Taxes paid, net (a) $ 2,850 $ 277 $ 274 (a) As the Company generally files its tax returns on a consolidated basis, taxes paid, net of refunds, includes all taxes paid by the Company, including those of the Company’s discontinued operations.

Quarterly Financial Data (Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data (Unaudited)	15. Quarterly Financial Data (Unaudited) The following table summarizes the quarterly financial data for 2015 and 2014. The per common share calculations for each of the quarters are based on the weighted-average number of common shares for each period; therefore, the sum of the quarters may not necessarily be equal to the full year per common share amount. 2015 First Second Third Fourth Revenue $ 143,343 $ 148,320 $ 152,607 $ 192,129 Cost of operations 57,877 60,407 59,552 69,475 Sales and marketing 32,476 32,570 32,850 40,129 General and administrative 21,453 23,002 22,942 24,183 Depreciation and amortization 8,245 7,592 7,266 7,418 Interest income 17 9 10 15 Interest expense 6,172 6,171 5,681 5,099 Loss on convertible notes — — 2,058 — Gain on investments — 139 — — Other expense — 4,100 — — Income before income tax provision 17,137 14,626 22,268 45,840 Income tax provision 7,133 1,255 9,080 18,379 Net income $ 10,004 $ 13,371 $ 13,188 $ 27,461 Net income per common share – Basic $ 0.27 $ 0.36 $ 0.36 $ 0.75 Net income per common share – Diluted $ 0.25 $ 0.32 $ 0.32 $ 0.60 Net Income per Common Share: Numerator: Net income – Basic $ 10,004 $ 13,371 $ 13,188 $ 27,461 Interest expense on 1.50% Notes, net of tax 864 864 864 864 Interest expense on 2.50% Notes, net of tax — 1,797 1,797 1,797 Interest expense on 2.25% Notes, net of tax — 1,103 — 449 Net income – Diluted $ 10,868 $ 17,135 $ 15,849 $ 30,571 Denominator: Weighted-average shares – Basic 36,393 36,705 36,721 36,583 Stock options and restricted stock 1,378 1,503 1,338 1,427 1.50% Notes 5,694 5,694 5,694 5,694 2.50% Notes — 6,205 6,205 6,205 2.25% Notes — 3,511 — 1,429 Adjusted weighted-average shares after assumed conversions – Diluted 43,465 53,618 49,958 51,338 2014 First Second Third Fourth Revenue $ 133,832 $ 140,400 $ 143,490 $ 162,727 Cost of operations 52,564 54,456 56,398 60,676 Sales and marketing 32,911 33,321 32,950 36,978 General and administrative 23,781 22,339 23,243 24,756 Depreciation and amortization 7,328 7,042 7,667 7,774 Interest income 15 17 19 18 Interest expense 6,172 6,172 6,171 6,171 Income from continuing operations before income tax provision 11,091 17,087 17,080 26,390 Income tax provision 4,825 7,371 7,275 11,236 Income from continuing operations 6,266 9,716 9,805 15,154 Income from discontinued operations, net of tax — — — 1,122 Net income $ 6,266 $ 9,716 $ 9,805 $ 16,276 Basic income per common share: Income from continuing operations $ 0.16 $ 0.26 $ 0.26 $ 0.42 Income from discontinued operations — — — 0.03 Net income $ 0.16 $ 0.26 $ 0.26 $ 0.45 Diluted income per common share: Income from continuing operations $ 0.15 $ 0.23 $ 0.23 $ 0.36 Income from discontinued operations — — — 0.02 Net income $ 0.15 $ 0.23 $ 0.23 $ 0.38 Net Income per Common Share: Numerator: Income from continuing operations – Basic $ 6,266 $ 9,716 $ 9,805 $ 15,154 Interest expense on 1.50% Notes, net of tax — 864 864 864 Interest expense on 2.50% Notes, net of tax — — — 1,797 Interest expense on 2.25% Notes, net of tax — — — 1,103 Income from continuing operations – Diluted $ 6,266 $ 10,580 $ 10,669 $ 18,918 Income from discontinued operations, net of tax – Basic and Diluted $ — $ — $ — $ 1,122 Denominator: Weighted-average shares – Basic 39,268 37,819 37,960 36,427 Stock options and restricted stock 2,584 2,301 2,113 1,245 1.50% Notes — 5,681 5,684 5,694 2.50% Notes — — — 6,205 2.25% Notes — — — 3,511 Adjusted weighted-average shares after assumed conversions – Diluted 41,852 45,801 45,757 53,082

Schedule II. Valuation and Qual

Schedule II. Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2015
Valuation and Qualifying Accounts [Abstract]
Schedule II. Valuation and Qualifying Accounts	Years Ended December 31, 2015, 2014 and 2013 Balance at Charged to Beginning Costs and Balance at of Year Expenses Write-offs Other End of Year (in thousands) December 31, 2015 Allowance for Doubtful Accounts $ 631 $ 874 $ (465 ) $ — $ 1,040 Valuation Allowance for Deferred Tax Assets 157,644 (7,061 ) — (7,979 ) (a) 142,604 December 31, 2014 Allowance for Doubtful Accounts 793 577 (739 ) — 631 Valuation Allowance for Deferred Tax Assets 174,592 (2,350 ) — (14,598 ) (b) 157,644 December 31, 2013 Allowance for Doubtful Accounts 1,304 283 (794 ) — 793 Valuation Allowance for Deferred Tax Assets 176,403 (1,831 ) — 20 174,592 (a) Primarily represents the valuation allowance released as a result of the utilization of net operating loss carryforwards generated by excess tax benefits of share-based payments, offset by a correcting adjustment, made in the quarter ended June 30, 2015, related to the realization of excess tax benefits of share-based payments during the years ended December 31, 2011 and 2010. (b) Primarily represents the valuation allowance released as a result of the utilization and expiration of net operating loss carryforwards generated by excess tax benefits of share-based payments.

Background and Basis of Prese24

Background and Basis of Presentation (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Background	Background WebMD Health Corp. (the “Company” or “WebMD”) is a Delaware corporation that was incorporated on May 3, 2005. The Company completed an initial public offering on September 28, 2005. The Company’s Common Stock trades under the symbol “WBMD” on the Nasdaq Global Select Market. The Company generates revenue from the advertising and sponsorship services of The WebMD Health Network WebMD Health Services Advertising and Sponsorship The WebMD Health Network www.WebMD.com www.Medscape.com WebMD Magazine Private Portal Services WebMD Health Services WebMD Health Services WebMD Health Services WebMD Health Services Information Services.
Basis of Presentation	Basis of Presentation The accompanying Consolidated Financial Statements include the consolidated accounts of the Company and its wholly-owned subsidiaries and have been prepared in United States dollars, and in accordance with U.S. generally accepted accounting principles (“GAAP”). The results of operations for companies acquired or disposed of are included in the Consolidated Financial Statements from the effective date of acquisition or up to the date of disposal. All material intercompany balances and transactions have been eliminated in consolidation.
Accounting Estimates	Accounting Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. The Company bases its estimates on historical experience, current business factors, and various other assumptions that the Company believes are necessary to consider to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company’s business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment changes. Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in reported results of operations; if material, the effects of changes in estimates are disclosed in the notes to the Consolidated Financial Statements. Significant estimates and assumptions by management affect the allowance for doubtful accounts, the carrying value of long-lived assets (including goodwill and intangible assets), the amortization period of long-lived assets (excluding goodwill and indefinite-lived intangible assets), the carrying value, capitalization and amortization of software and Website development costs, the carrying value of investments, the provision for income taxes and related deferred tax accounts, certain accrued liabilities, revenue recognition, contingencies, litigation and related legal accruals and the value attributed to employee stock options and other stock-based awards.
Seasonality	Seasonality The timing of the Company’s revenue is affected by seasonal factors. The Company’s public portal advertising and sponsorship revenue is seasonal, primarily due to the annual spending patterns of the advertising and sponsorship clients of the Company’s public portals. This portion of the Company’s revenue is usually the lowest in the first quarter of each calendar year, and generally increases during each consecutive quarter throughout the year. The timing of revenue in relation to the Company’s expenses, many of which do not vary directly with revenue, has an impact on cost of operations, sales and marketing, and general and administrative expenses as a percentage of revenue in each calendar quarter.
Cash and Cash Equivalents	Cash and Cash Equivalents All highly liquid investments with an original maturity from the date of purchase of three months or less are considered to be cash equivalents. These investments are stated at cost, which approximates market. The Company’s cash and cash equivalents are generally invested in various money market accounts.
Fair Value	Fair Value The carrying amount of cash and cash equivalents, accounts receivable, accrued expenses and deferred revenue is deemed to approximate fair value due to the immediate or short-term maturity of these financial instruments. See Note 12 for further information on the fair value of the Company’s investments.
Allowance for Doubtful Accounts	Allowance for Doubtful Accounts The allowance for doubtful accounts receivable reflects the Company’s best estimate of losses inherent in the Company’s receivable portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available evidence.
Long-Lived Assets	Long-Lived Assets Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets. The useful lives are generally as follows: Computer equipment 3 to 5 years Office equipment, furniture and fixtures 4 to 7 years Software 3 years Building and improvements Up to 40 years Website development costs 3 years Leasehold improvements Shorter of useful life or lease term Expenditures for maintenance, repair and renewals of minor items are charged to expense as incurred. Major improvements are capitalized. Goodwill and Intangible Assets Goodwill and intangible assets result from business combinations accounted for under the acquisition method. Goodwill and other intangible assets with indefinite lives are not amortized and are subjected to impairment review by applying fair value based tests. Intangible assets with definite lives are amortized on a straight-line basis over the individually estimated useful lives of the related assets as follows: Content 3 to 5 years Customer relationships 5 to 12 years Acquired technology and patents 3 years Trade names Up to 10 years Recoverability The Company reviews the carrying value of goodwill and indefinite-lived intangible assets annually and whenever indicators of impairment are present. The Company has one reporting unit and tests goodwill for impairment at the reporting unit level only when, after completing a qualitative analysis, it is determined that it is more likely than not that the fair value of the reporting unit is less than its carrying value. Fair value is determined using an income approach valuation. A reporting unit is defined as an operating segment or one level below an operating segment. Long-lived assets used in operations are reviewed for impairment whenever events or changes in circumstances indicate that carrying amounts may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and the fair value. Long-lived assets held for sale are reported at the lower of cost or fair value less costs to sell. Based on the Company’s analysis, there was no impairment of goodwill or indefinite-lived intangible assets during the years ended December 31, 2015, 2014 and 2013.
Leases	Leases The Company recognizes rent expense on a straight-line basis, including predetermined fixed escalations, over the initial lease term including reasonably assured renewal periods, net of lease incentives, from the time that the Company controls the leased property. Leasehold improvements made at the inception of the lease are amortized over the shorter of the useful life of the asset or the lease term. Lease incentives are recorded as a deferred credit and recognized as a reduction to rent expense on a straight-line basis over the lease term as described above.
Internal Use Software	Internal Use Software Software development costs that are incurred in the preliminary project stage are expensed as incurred. Once certain criteria have been met, direct costs incurred in developing or obtaining computer software are capitalized. The Company capitalized $6,441 and $5,369 during the years ended December 31, 2015 and 2014, respectively. Capitalized internal use software development costs are included in property and equipment in the accompanying consolidated balance sheets. Training and data conversion costs are expensed as incurred. Capitalized software costs are depreciated over a three-year period. Depreciation expense related to internal use software was $6,403, $6,449 and $5,070 for the years ended December 31, 2015, 2014 and 2013, respectively. The remaining balance of internal use software, net of accumulated depreciation, was $11,630 and $11,597 as of December 31, 2015 and 2014, respectively.
Website Development Costs	Website Development Costs Costs related to the planning and post-implementation phases of WebMD’s Website development efforts, as well as minor enhancements and maintenance, are expensed as incurred. Direct costs incurred in the development phase are capitalized. The Company capitalized $4,861 and $5,539 during the years ended December 31, 2015 and 2014, respectively. These capitalized costs are included in property and equipment in the accompanying consolidated balance sheets and are depreciated over a three-year period. Depreciation expense related to Website development costs was $6,580, $6,421 and $5,696 during the years ended December 31, 2015, 2014 and 2013, respectively. The remaining balance of Website development costs, net of accumulated depreciation, was $9,624 and $11,343 as of December 31, 2015 and 2014, respectively.
Restricted Cash	Restricted Cash The Company’s restricted cash primarily relates to collateral for letters of credit obtained to support the Company’s operations. Total restricted cash was $3,547 and $1,765 as of December 31, 2015 and 2014, respectively, and is included in other assets in the accompanying consolidated balance sheets.
Deferred Charges	Deferred Charges Other assets includes costs associated with the issuance of the Company’s convertible notes that are amortized to interest expense in the accompanying consolidated statements of operations, using the effective interest method over the period from issuance through the earliest date on which holders can demand redemption. During the year ended December 31, 2011, the Company capitalized issuance costs of $12,655 and $12,595, related to the issuance of its 2.50% Convertible Notes due 2018 (the “2.50% Notes”) and its 2.25% Convertible Notes due 2016 (the “2.25% Notes”), respectively. Additionally, during the year ended December 31, 2013, the Company capitalized $8,177 of issuance costs in connection with the 2013 issuance of its 1.50% Convertible Notes due 2020 (the “1.50% Notes”). The aggregate amortization of these issuance costs, which is included within interest expense in the accompanying consolidated statements of operations, was $4,172, $4,511 and $4,192 for the years ended December 31, 2015, 2014 and 2013, respectively. During the years ended December 31, 2015 and 2013, the Company wrote off issuance costs of $571 and $2,285, respectively, in connection with the repurchase of a portion of its 2.25% Notes. As of December 31, 2015 and 2014, there were $9,612 and $14,355, respectively, of unamortized issuance costs included in other assets within the accompanying consolidated balance sheets.
Deferred Revenue	Deferred Revenue Deferred revenue consists of invoices sent to customers or payments received from customers, in advance of revenue recognition and is recognized as the revenue recognition criteria are met. Deferred revenue is influenced by several factors, including the timing of invoices to our customers and the timing of payments received from our customers in relation to the timing of the revenue recognition for the related customer contract. Deferred revenue at each balance sheet date is expected to be recognized during the succeeding twelve month period and is therefore classified as a current liability within the accompanying consolidated balance sheets.
Presentation of Segment Information	Presentation of Segment Information The Company generates revenue in four groups, as set forth in the table below. The first group is “Advertising and Sponsorship – Biopharma and Medical Device” and consists of advertising and sponsorship revenue from pharmaceutical, biotechnology and medical device clients relating to ethical pharmaceutical products or other regulated devices or products or for sponsoring educational programs. The second category is “Advertising and Sponsorship – OTC, CPG and Other” and consists of advertising and sponsorship revenue relating to non-Rx or over-the-counter medications and other healthcare products, food and beverages, beauty products and other consumer products, as well as revenue from clients such as retailers, pharmacies, hospitals, health insurance companies and government agencies. The combined revenue of the first two groups is sometimes referred to as “Advertising and Sponsorship” revenue. The third group is “Private Portal Services” and consists of revenue from employers and health plans for subscriptions to the Company’s private portals solution and related services, including health coaching and condition management services. The fourth group is “Information Services” and consists of revenue from the sale of stand-alone information and data products. Discrete financial information related to a measure of profit or loss for these four revenue groups is not available as they leverage many common expenses, and the Company does not separately allocate these common expenses in assessing the performance of its business. Accordingly, the Company views its business as one reportable segment. The following table presents the revenues recognized from the four revenue groups described above: Years Ended December 31, 2015 2014 2013 Advertising and sponsorship Biopharma and medical device $ 371,220 $ 329,329 $ 304,018 OTC, CPG and other 127,805 124,636 113,009 499,025 453,965 417,027 Private portal services 110,441 103,182 82,111 Information services 26,933 23,302 16,155 $ 636,399 $ 580,449 $ 515,293 The Company’s revenue is principally generated in the United States. An adverse change in economic conditions in the United States could negatively affect the Company’s revenue and results of operations. The Company recorded revenue from its international operations of $56,979, $46,095 and $31,340 during the years ended December 31, 2015, 2014 and 2013, respectively.
Sales, Use and Value Added Tax	Sales, Use and Value Added Tax The Company excludes sales, use and value-added tax from revenue in the accompanying consolidated statements of operations.
Advertising Costs	Advertising Costs Advertising costs are generally expensed as incurred and totaled $4,359, $4,196 and $5,174 in 2015, 2014 and 2013, respectively.
Foreign Currency	Foreign Currency The functional currency of the Company’s foreign operations is the U.S. dollar. Fluctuations in foreign currency monetary assets and liabilities result in gains or losses which are credited or charged to income. Foreign currency transactional gains or losses are also credited or charged to income.
Concentration of Credit Risk	Concentration of Credit Risk None of the Company’s customers individually accounted for more than 10% of the Company’s revenue in 2015, 2014 or 2013 or more than 10% of the Company’s accounts receivable as of December 31, 2015 or 2014.
Loss Contingencies	Loss Contingencies The Company accounts for loss contingencies in accordance with Financial Accounting Standards Board (“FASB”) ASC No. 450, “Contingencies.” Under ASC No. 450, accruals for loss contingencies are recorded when both (i) the information available indicates that it is probable that a liability has been incurred and (ii) the amount of the loss can be reasonably estimated. The Company records adjustments to these accruals to reflect the status of negotiations, settlements, advice of counsel and other information and events related to an individual matter.
Income Taxes	Income Taxes Deferred income taxes are recognized for the future tax consequence of differences between the tax and financial reporting basis of assets and liabilities at each reporting period. A valuation allowance is established to reduce deferred tax assets to the amount expected to be realized. Tax contingencies are recorded to address potential exposure involving tax positions the Company has taken that could be challenged by tax authorities. These potential exposures result from applications of various statutes, rules, regulations and interpretations. The Company’s estimates of tax contingencies contain assumptions and judgments about potential actions by taxing jurisdictions. The Company reflects interest and penalties related to uncertain tax positions as part of the income tax provision in the accompanying consolidated statements of operations.
Accounting for Stock-Based Compensation	Accounting for Stock-Based Compensation Stock-based compensation expense for all share-based payment awards granted is determined based on the grant-date fair value. The grant-date fair value for stock options is estimated using the Black-Scholes Option Pricing Model. The Company recognizes these compensation costs net of an estimated forfeiture rate on a straight-line basis over the requisite service period of the award, which is generally the vesting term of the share-based payment award.
Revenue Recognition	Revenue Recognition Revenue from advertising is recognized as advertisements are delivered or as publications are distributed. Revenue from sponsorship arrangements, content syndication and distribution arrangements and subscriptions to healthcare management tools and private portals as well as related health coaching services is recognized ratably over the term of the applicable agreement. Revenue from information services is recognized as the underlying data is delivered. Revenue from the sponsorship of CME is recognized over the period the Company substantially completes its contractual deliverables as determined by the applicable agreements. Contracts that contain multiple deliverables are subject to Accounting Standards Update (“ASU”) No. 2009-13 Multiple-Deliverable Revenue Arrangements (“ASU 2009-13”). ASU 2009-13 requires the allocation of revenue to each deliverable of multiple-deliverable revenue arrangements, based on the relative selling price of each deliverable. It also defines the level of evidence of selling price required to separate deliverables and allows a company to make its best estimate of the selling price of deliverables when more objective evidence of selling price is not available. Pursuant to the guidance of ASU 2009-13, when a sales arrangement contains multiple deliverables, the Company allocates revenue to each deliverable based on relative selling price. The selling price for a deliverable is based on vendor-specific objective evidence (“VSOE”) if available, third-party evidence (“TPE”) if VSOE is not available, or best estimate of selling price if neither VSOE nor TPE is available. The Company then recognizes revenue on each deliverable in accordance with its revenue recognition policies over the period that delivery occurs. VSOE of selling price is based on the price charged when the deliverable is sold separately. In determining VSOE, GAAP requires that a substantial majority of the selling prices fall within a reasonable range based on historical pricing trends for specific products and services. TPE is based on competitor prices of similar deliverables when sold separately. The Company is not able to determine TPE of selling price as it is unable to reliably determine what competitors’ selling prices are for comparable services, combined with the fact that its services often contain unique features and customizations such that comparable services do not exist. The determination of best estimate of selling price is a judgmental process that considers multiple factors including, but not limited to, recent selling prices and related discounting practices for each service, market conditions, customer classes, sales channels and other factors.
Net Income Per Common Share	Net Income Per Common Share Basic income per common share has been computed using the weighted-average number of shares of Common Stock outstanding during the periods presented. Diluted income per common share has been computed using the weighted-average number of shares of Common Stock outstanding during the periods, increased to give effect to potentially dilutive securities and assumes that any dilutive convertible notes were converted, only in the periods in which such effect is dilutive (shares in thousands): Years Ended December 31, 2015 2014 2013 Numerator: Income from continuing operations – Basic $ 64,024 $ 40,941 $ 15,116 Interest expense on 1.50% Notes, net of tax 3,456 3,456 — Interest expense on 2.50% Notes, net of tax 7,189 — — Interest expense on 2.25% Notes, net of tax 3,460 — — Income from continuing operations – Diluted $ 78,129 $ 44,397 $ 15,116 Income from discontinued operations, net of tax – Basic and Diluted $ — $ 1,122 $ — Denominator: Weighted-average shares – Basic 36,600 37,869 46,830 Stock options and restricted stock 1,412 2,060 1,568 1.50% Notes 5,694 5,685 — 2.50% Notes 6,205 — — 2.25% Notes 2,742 — — Adjusted weighted-average shares after assumed conversions – Diluted 52,653 45,614 48,398 Basic income per common share: Income from continuing operations $ 1.75 $ 1.08 $ 0.32 Income from discontinued operations — 0.03 — Net income $ 1.75 $ 1.11 $ 0.32 Diluted income per common share: Income from continuing operations $ 1.48 $ 0.97 $ 0.31 Income from discontinued operations — 0.03 — Net income $ 1.48 $ 1.00 $ 0.31 The Company has excluded certain of its convertible notes, as well as certain outstanding stock options and restricted stock, from the calculation of diluted income per common share during the periods in which such securities were anti-dilutive. The following table presents the total weighted-average number of potentially dilutive common shares that were excluded from the computation of diluted income per common share during the periods presented (shares in thousands): Years Ended December 31, 2015 2014 2013 Options and restricted stock 3,678 2,594 5,744 1.50% Notes — — 556 2.25% Notes — 3,506 5,020 2.50% Notes — 6,195 6,148 3,678 12,295 17,468
Discontinued Operations	Discontinued Operations A business unit is reported as a discontinued operation if its disposal represents a strategic shift that has, or will have, a major effect on the Company’s operations and financial results. Significant judgments are involved in determining whether a business component meets the criteria for discontinued operation reporting and the period in which these criteria are met .
Recent Accounting Pronouncements	Recent Accounting Pronouncements Accounting Pronouncement Adopted During 2015 In April 2014, the FASB issued ASU No. 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity Accounting Pronouncements to be Adopted in the Future In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date In June 2014, the FASB issued ASU No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period In April 2015, the FASB issued ASU No. 2015-03, Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs In April 2015, the FASB issued ASU No. 2015-05, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU No. 2016-01, Leases (Topic 842)

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Property and Equipment Estimated Useful Lives	The useful lives are generally as follows: Computer equipment 3 to 5 years Office equipment, furniture and fixtures 4 to 7 years Software 3 years Building and improvements Up to 40 years Website development costs 3 years Leasehold improvements Shorter of useful life or lease term
Intangible Assets with Definite Lives are Amortized on Straight-Line Basis over Individually Estimated Useful Lives of Related Assets	Intangible assets with definite lives are amortized on a straight-line basis over the individually estimated useful lives of the related assets as follows: Content 3 to 5 years Customer relationships 5 to 12 years Acquired technology and patents 3 years Trade names Up to 10 years
Summary of Revenues from Four Revenue Groups	The following table presents the revenues recognized from the four revenue groups described above: Years Ended December 31, 2015 2014 2013 Advertising and sponsorship Biopharma and medical device $ 371,220 $ 329,329 $ 304,018 OTC, CPG and other 127,805 124,636 113,009 499,025 453,965 417,027 Private portal services 110,441 103,182 82,111 Information services 26,933 23,302 16,155 $ 636,399 $ 580,449 $ 515,293
Schedule of Net Income Per Common Shares	Basic income per common share has been computed using the weighted-average number of shares of Common Stock outstanding during the periods presented. Diluted income per common share has been computed using the weighted-average number of shares of Common Stock outstanding during the periods, increased to give effect to potentially dilutive securities and assumes that any dilutive convertible notes were converted, only in the periods in which such effect is dilutive (shares in thousands): Years Ended December 31, 2015 2014 2013 Numerator: Income from continuing operations – Basic $ 64,024 $ 40,941 $ 15,116 Interest expense on 1.50% Notes, net of tax 3,456 3,456 — Interest expense on 2.50% Notes, net of tax 7,189 — — Interest expense on 2.25% Notes, net of tax 3,460 — — Income from continuing operations – Diluted $ 78,129 $ 44,397 $ 15,116 Income from discontinued operations, net of tax – Basic and Diluted $ — $ 1,122 $ — Denominator: Weighted-average shares – Basic 36,600 37,869 46,830 Stock options and restricted stock 1,412 2,060 1,568 1.50% Notes 5,694 5,685 — 2.50% Notes 6,205 — — 2.25% Notes 2,742 — — Adjusted weighted-average shares after assumed conversions – Diluted 52,653 45,614 48,398 Basic income per common share: Income from continuing operations $ 1.75 $ 1.08 $ 0.32 Income from discontinued operations — 0.03 — Net income $ 1.75 $ 1.11 $ 0.32 Diluted income per common share: Income from continuing operations $ 1.48 $ 0.97 $ 0.31 Income from discontinued operations — 0.03 — Net income $ 1.48 $ 1.00 $ 0.31
Weighted Average Number of Potentially Dilutive Common Shares Excluded from Computation of Diluted Income Per Common Share	The Company has excluded certain of its convertible notes, as well as certain outstanding stock options and restricted stock, from the calculation of diluted income per common share during the periods in which such securities were anti-dilutive. The following table presents the total weighted-average number of potentially dilutive common shares that were excluded from the computation of diluted income per common share during the periods presented (shares in thousands): Years Ended December 31, 2015 2014 2013 Options and restricted stock 3,678 2,594 5,744 1.50% Notes — — 556 2.25% Notes — 3,506 5,020 2.50% Notes — 6,195 6,148 3,678 12,295 17,468

Long-Lived Assets (Tables)

Long-Lived Assets (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Components of Property and Equipment	Property and equipment consist of the following: December 31, 2015 2014 Software $ 66,708 $ 60,341 Computer equipment 69,973 63,541 Web site development costs 62,784 57,922 Leasehold improvements 72,679 44,000 Office equipment, furniture and fixtures 17,398 15,154 Land and buildings 291 291 289,833 241,249 Less: accumulated depreciation (208,806 ) (181,676 ) Property and equipment, net $ 81,027 $ 59,573
Schedule of Finite and Indefinite Lived Intangible Assets	Intangible assets consist of the following: December 31, 2015 December 31, 2014 Weighted Weighted Gross Average Gross Average Carrying Accumulated Remaining Carrying Accumulated Remaining Amount Amortization Net Useful Life (a) Amount Amortization Net Useful Life (a) Content $ 15,954 $ (15,954 ) $ — — $ 15,954 $ (15,954 ) $ — — Customer relationships 34,057 (29,218 ) 4,839 2.7 34,057 (27,126 ) 6,931 3.6 Technology and patents 17,882 (16,291 ) 1,591 1.5 17,882 (15,231 ) 2,651 2.5 Trade names-definite lives 2,530 (2,530 ) — — 2,530 (2,361 ) 169 1.0 Trade names-indefinite lives 4,464 — 4,464 n/a 4,464 — 4,464 n/a Total $ 74,887 $ (63,993 ) $ 10,894 $ 74,887 $ (60,672 ) $ 14,215 (a) The calculation of the weighted average remaining useful life is based on the net book value and the remaining amortization period of each respective intangible asset.
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Amortization expense was $3,321, $2,801 and $2,271 in 2015, 2014 and 2013, respectively. Future amortization expense for intangible assets is estimated to be: Year Ending December 31: 2016 $ 3,120 2017 $ 2,044 2018 $ 1,266

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Components of Accrued Expenses	Accrued expenses consist of the following: December 31, 2015 2014 Accrued compensation $ 45,715 $ 38,856 Accrued outside services 10,775 11,089 Accrued marketing and distribution 5,383 4,442 Accrued interest 5,119 5,960 Other accrued liabilities 13,672 12,311 $ 80,664 $ 72,658

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Commitments	Future minimum lease commitments under non-cancelable lease agreements at December 31, 2015 were as follows: Year Ending December 31: 2016 $ 14,773 2017 15,122 2018 14,826 2019 14,035 2020 14,414 Thereafter 33,697 Total minimum lease payments $ 106,867

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-Based Compensation, Stock Options, Activity	The following table summarizes stock option activity for the Plans: Shares Weighted Weighted Aggregate (a) Outstanding at January 1, 2013 13,300,688 $ 26.24 Granted 2,844,500 33.64 Exercised (2,695,600 ) 20.90 Cancelled (2,020,309 ) 27.50 Outstanding at December 31, 2013 11,429,279 29.12 Granted 899,200 43.03 Exercised (3,875,410 ) 24.40 Cancelled (905,543 ) 33.42 Outstanding at December 31, 2014 7,547,526 32.69 Granted 2,134,900 42.75 Exercised (989,993 ) 24.53 Cancelled (821,998 ) 38.68 Outstanding at December 31, 2015 7,870,435 $ 35.81 6.7 $ 99,384 Vested and exercisable at the end of the period 4,101,045 $ 32.22 5.1 $ 67,010 (a) The aggregate intrinsic value is based on the market price of the Company’s Common Stock on December 31, 2015, which was $48.30, less the applicable exercise price of the underlying option. This aggregate intrinsic value represents the amount that would have been realized if all the option holders had exercised their options on December 31, 2015.
Summarized Information with Respect to Options Outstanding and Options Exercisable	The following table summarizes information with respect to options outstanding and options exercisable at December 31, 2015: Outstanding Exercisable Exercise Prices Shares Weighted Weighted Shares Weighted $13.15 - $19.95 532,595 $ 13.50 6.9 465,720 $ 13.31 $20.21 - $25.99 636,867 22.78 4.4 497,217 22.80 $26.03 - $29.92 838,411 28.08 4.0 791,961 28.07 $30.00 - $33.40 1,037,794 32.15 6.8 703,044 31.64 $33.55 - $38.60 658,575 36.73 5.9 465,187 36.85 $38.65 - $39.50 1,019,918 39.07 7.9 326,258 39.05 $39.51 - $42.98 531,500 40.56 6.8 170,500 40.84 $42.99 1,336,000 42.99 9.2 — — $43.05 - $46.46 637,000 44.72 8.3 134,200 45.46 $46.50 - $58.96 641,775 49.46 4.7 546,958 49.70 7,870,435 $ 35.81 6.7 4,101,045 $ 32.22
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The risk-free rate is based on the U.S. Treasury yield curve for periods equal to the expected term of the options on the grant date. Years Ended December 31, 2015 2014 2013 Expected dividend yield 0.0 % 0.0 % 0.0 % Expected volatility 0.41 - 0.48 0.47 - 0.49 0.43 - 0.48 Risk-free interest rate 1.01% - 1.56 % 1.16% - 1.72 % 0.55% - 1.62 % Expected term (years) 4.1 - 4.7 4.2 - 5.0 4.5 - 5.1 Weighted-average fair value of options granted during the period $ 16.26 $ 17.58 $ 13.95
Schedule of Share-based Compensation, Restricted Stock Awards, Activity	The following table summarizes the activity of the Company’s Restricted Stock: Years Ended December 31, 2015 2014 2013 Shares Weighted Shares Weighted Shares Weighted Balance at beginning of the year 904,083 $ 35.58 1,184,961 $ 33.07 932,386 $ 31.69 Granted 441,920 42.96 177,200 43.84 812,000 32.65 Vested (331,558 ) 35.72 (324,453 ) 32.70 (401,825 ) 32.57 Forfeited (159,600 ) 36.57 (133,625 ) 31.29 (157,600 ) 24.02 Balance at the end of the year 854,845 $ 39.17 904,083 $ 35.58 1,184,961 $ 33.07
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	The following table summarizes the components and classification of stock-based compensation expense: Years Ended December 31, 2015 2014 2013 Stock options $ 21,336 $ 21,117 $ 24,483 Restricted stock 11,940 11,114 13,703 Other 467 315 364 Total stock-based compensation expense $ 33,743 $ 32,546 $ 38,550 Included in: Cost of operations $ 5,217 $ 5,940 $ 6,762 Sales and marketing 7,290 7,221 8,395 General and administrative 21,236 19,385 23,393 Total stock-based compensation expense $ 33,743 $ 32,546 $ 38,550

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Significant Components of the Company's Deferred Tax Assets (Liabilities)	Significant components of the Company’s deferred tax assets (liabilities) were as follows: December 31, 2015 2014 Deferred tax assets: Federal net operating loss carryforwards $ 83,071 $ 91,000 State net operating loss carryforwards 33,320 35,488 Capital losses 292 458 Federal tax credits 28,555 56,096 Accrued expenses 19,086 17,919 Stock-based compensation 24,294 21,031 Intangible assets 3,610 3,570 Other 3,808 3,841 Total deferred tax assets 196,036 229,403 Valuation allowance (142,604 ) (157,644 ) Net deferred tax assets 53,432 71,759 Deferred tax liabilities: Property and equipment (1,466 ) (3,063 ) Goodwill and indefinite-lived intangible asset (33,465 ) (30,975 ) Other (2,807 ) (627 ) Total deferred tax liabilities (37,738 ) (34,665 ) Net deferred tax assets $ 15,694 $ 37,094 December 31, 2015 2014 Current deferred tax assets, net: Current deferred tax assets, net of deferred tax liabilities $ 66,665 $ 59,371 Valuation allowance (50,539 ) (41,224 ) Current deferred tax assets, net 16,126 18,147 Non-current deferred tax (liabilities) assets, net: Non-current deferred tax assets, net of deferred tax liabilities 91,633 135,367 Valuation allowance (92,065 ) (116,420 ) Non-current deferred tax (liabilities) assets, net (432 ) 18,947 Net deferred tax assets $ 15,694 $ 37,094
Income Tax Provision	The income tax provision was as follows: Years Ended December 31, 2015 2014 2013 Current: Federal $ 1,076 $ (622 ) $ (73 ) State 4,773 3,047 502 Foreign 268 369 141 Current income tax provision 6,117 2,794 570 Deferred: Federal (8,456 ) 12,570 10,683 State 743 2,147 2,387 Deferred income tax (benefit) provision (7,713 ) 14,717 13,070 Reversal of valuation allowance applied to additional paid-in capital 37,443 13,196 — Total income tax provision $ 35,847 $ 30,707 $ 13,640
Reconciliation between Federal Statutory Rate and Effective Income Tax Rate	The reconciliation between the federal statutory rate and the effective income tax rate is as follows: Years Ended December 31, 2015 2014 2013 United States federal statutory rate 35.0% 35.0% 35.0% State income taxes (net of federal benefit) 5.7 7.4 12.5 Valuation allowance (7.1) (3.3) (6.4) Non-deductible officer compensation 1.4 2.2 3.6 Other 0.9 1.6 2.7 Effective income tax rate 35.9% 42.9% 47.4%
Activity of Unrecognized Tax Benefits, Excluding Accrued Interest and Penalties	The following table summarizes the activity of unrecognized tax benefits, excluding accrued interest and penalties, for the years ended December 31, 2015, 2014 and 2013: Years Ended December 31, 2015 2014 2013 Balance at the beginning of the year $ 12,972 $ 13,392 $ 13,949 Increases related to prior year tax positions 776 15 — Increases related to current year tax positions 394 — — Decreases related to prior year tax positions — (379 ) (532 ) Settlements (15 ) — — Expiration of the statute of limitations for the assessment of taxes (50 ) (56 ) (25 ) Balance at the end of the year $ 14,077 $ 12,972 $ 13,392

Fair Value of Financial Instr31

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Financial Assets Measured and Recorded at Fair Value on Recurring Basis	The following table sets forth the Company’s Level 1 financial assets that were measured and recorded at fair value on a recurring basis as of December 31, 2015 and 2014: Fair Value Estimate Using: December 31, 2015 December 31, 2014 Amortized Cost Basis Fair Value Gross Unrealized Gains Amortized Cost Basis Fair Value Gross Unrealized Gains Cash and cash equivalents Level 1 $ 641,165 $ 641,165 $ — $ 706,776 $ 706,776 $ — Available-for-sale security Level 1 — 598 598 — 1,603 1,603
Reconciliation of Beginning and Ending Balances of Available-for-sale Security	The following table reconciles the beginning and ending balances of the Company’s available-for-sale security during the year ended December 31, 2015: Year Ended Fair value as of the beginning of the period $ 1,603 Cash proceeds received (139 ) Gain included in earnings 139 Change in unrealized gains included in other comprehensive income (1,005 ) Fair value as of the end of the period $ 598
Carrying Value and Estimated Fair Value of Company's Convertible Notes that are Carried at Historical Cost	The following table presents the carrying value and estimated fair value (based on Level 1 market price data) of the Company’s convertible notes that were carried at historical cost as of December 31, 2015 and 2014: December 31, 2015 December 31, 2014 Carrying Fair Value Carrying Fair Value 2.25% Notes $ 102,682 $ 102,618 $ 252,232 $ 254,754 2.50% Notes $ 400,000 $ 416,000 $ 400,000 $ 399,000 1.50% Notes $ 300,000 $ 340,566 $ 300,000 $ 299,250

Supplemental Disclosures of C32

Supplemental Disclosures of Cash Flow Information (Tables)	12 Months Ended
	Dec. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Supplemental Disclosure of Cash Flow Information	Supplemental information related to the consolidated statements of cash flows is summarized below: Years Ended December 31, 2015 2014 2013 Supplemental Disclosure of Cash Flow Information: Interest paid $ 19,792 $ 20,225 $ 19,038 Taxes paid, net (a) $ 2,850 $ 277 $ 274 (a) As the Company generally files its tax returns on a consolidated basis, taxes paid, net of refunds, includes all taxes paid by the Company, including those of the Company’s discontinued operations.

Quarterly Financial Data (Una33

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data	The following table summarizes the quarterly financial data for 2015 and 2014. The per common share calculations for each of the quarters are based on the weighted-average number of common shares for each period; therefore, the sum of the quarters may not necessarily be equal to the full year per common share amount. 2015 First Second Third Fourth Revenue $ 143,343 $ 148,320 $ 152,607 $ 192,129 Cost of operations 57,877 60,407 59,552 69,475 Sales and marketing 32,476 32,570 32,850 40,129 General and administrative 21,453 23,002 22,942 24,183 Depreciation and amortization 8,245 7,592 7,266 7,418 Interest income 17 9 10 15 Interest expense 6,172 6,171 5,681 5,099 Loss on convertible notes — — 2,058 — Gain on investments — 139 — — Other expense — 4,100 — — Income before income tax provision 17,137 14,626 22,268 45,840 Income tax provision 7,133 1,255 9,080 18,379 Net income $ 10,004 $ 13,371 $ 13,188 $ 27,461 Net income per common share – Basic $ 0.27 $ 0.36 $ 0.36 $ 0.75 Net income per common share – Diluted $ 0.25 $ 0.32 $ 0.32 $ 0.60 Net Income per Common Share: Numerator: Net income – Basic $ 10,004 $ 13,371 $ 13,188 $ 27,461 Interest expense on 1.50% Notes, net of tax 864 864 864 864 Interest expense on 2.50% Notes, net of tax — 1,797 1,797 1,797 Interest expense on 2.25% Notes, net of tax — 1,103 — 449 Net income – Diluted $ 10,868 $ 17,135 $ 15,849 $ 30,571 Denominator: Weighted-average shares – Basic 36,393 36,705 36,721 36,583 Stock options and restricted stock 1,378 1,503 1,338 1,427 1.50% Notes 5,694 5,694 5,694 5,694 2.50% Notes — 6,205 6,205 6,205 2.25% Notes — 3,511 — 1,429 Adjusted weighted-average shares after assumed conversions – Diluted 43,465 53,618 49,958 51,338 2014 First Second Third Fourth Revenue $ 133,832 $ 140,400 $ 143,490 $ 162,727 Cost of operations 52,564 54,456 56,398 60,676 Sales and marketing 32,911 33,321 32,950 36,978 General and administrative 23,781 22,339 23,243 24,756 Depreciation and amortization 7,328 7,042 7,667 7,774 Interest income 15 17 19 18 Interest expense 6,172 6,172 6,171 6,171 Income from continuing operations before income tax provision 11,091 17,087 17,080 26,390 Income tax provision 4,825 7,371 7,275 11,236 Income from continuing operations 6,266 9,716 9,805 15,154 Income from discontinued operations, net of tax — — — 1,122 Net income $ 6,266 $ 9,716 $ 9,805 $ 16,276 Basic income per common share: Income from continuing operations $ 0.16 $ 0.26 $ 0.26 $ 0.42 Income from discontinued operations — — — 0.03 Net income $ 0.16 $ 0.26 $ 0.26 $ 0.45 Diluted income per common share: Income from continuing operations $ 0.15 $ 0.23 $ 0.23 $ 0.36 Income from discontinued operations — — — 0.02 Net income $ 0.15 $ 0.23 $ 0.23 $ 0.38 Net Income per Common Share: Numerator: Income from continuing operations – Basic $ 6,266 $ 9,716 $ 9,805 $ 15,154 Interest expense on 1.50% Notes, net of tax — 864 864 864 Interest expense on 2.50% Notes, net of tax — — — 1,797 Interest expense on 2.25% Notes, net of tax — — — 1,103 Income from continuing operations – Diluted $ 6,266 $ 10,580 $ 10,669 $ 18,918 Income from discontinued operations, net of tax – Basic and Diluted $ — $ — $ — $ 1,122 Denominator: Weighted-average shares – Basic 39,268 37,819 37,960 36,427 Stock options and restricted stock 2,584 2,301 2,113 1,245 1.50% Notes — 5,681 5,684 5,694 2.50% Notes — — — 6,205 2.25% Notes — — — 3,511 Adjusted weighted-average shares after assumed conversions – Diluted 41,852 45,801 45,757 53,082

Summary of Significant Accoun34

Summary of Significant Accounting Policies - Property and Equipment Estimated Useful Lives (Detail)	12 Months Ended
	Dec. 31, 2015
Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Useful life	3 years
Website Development Costs [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Useful life	3 years
Minimum [Member] | Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Useful life	3 years
Minimum [Member] | Office Equipment, Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Useful life	4 years
Minimum [Member] | Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Useful life	Shorter of useful life or lease term
Maximum [Member] | Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Useful life	5 years
Maximum [Member] | Office Equipment, Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Useful life	7 years
Maximum [Member] | Building and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Useful life	40 years

Summary of Significant Accoun35

Summary of Significant Accounting Policies - Intangible Assets with Definite Lives are Amortized on Straight-Line Basis over Individually Estimated Useful Lives of Related Asset (Detail)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Useful Life	2 years 8 months 12 days	3 years 7 months 6 days
Minimum [Member] | Content [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Useful Life	3 years
Minimum [Member] | Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Useful Life	5 years
Maximum [Member] | Content [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Useful Life	5 years
Maximum [Member] | Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Useful Life	12 years
Maximum [Member] | Acquired Technology and Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Useful Life	3 years
Maximum [Member] | Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Useful Life	10 years

Summary of Significant Accoun36

Summary of Significant Accounting Policies - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)UnitSegment	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2011USD ($)
Summary Of Significant Accounting Policies [Line Items]
Number of reporting unit | Unit	1
Goodwill or indefinite-lived intangible assets impairment charge	$ 0	$ 0	$ 0
Depreciation expense	27,200	27,010	24,335
Property and equipment, net	81,027	59,573
Restricted cash	3,547	1,765
Amortization of debt issuance costs	4,172	4,511	4,192
Unamortized issuance cost	$ 9,612	14,355
Reportable segments | Segment	1
Advertising expense	$ 4,359	4,196	5,174
Foreign Country Customers [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenue from international operations	$ 56,979	$ 46,095	$ 31,340
2.50% Convertible Notes Due 2018 [Member]
Summary Of Significant Accounting Policies [Line Items]
Issuance costs capitalized				$ 12,655
Interest on convertible notes	2.50%			2.50%
Debt instrument, maturity date				2,018
2.25% Convertible Notes Due 2016 [Member]
Summary Of Significant Accounting Policies [Line Items]
Issuance costs capitalized				$ 12,595
Interest on convertible notes	2.25%		2.25%	2.25%
Debt instrument, maturity date				2,016
Issuance costs written off	$ 571		$ 2,285
1.50% Convertible Notes Due 2020 [Member]
Summary Of Significant Accounting Policies [Line Items]
Issuance costs capitalized			$ 8,177
Interest on convertible notes	1.50%	1.50%	1.50%
Debt instrument, maturity date			2,020
Software [Member]
Summary Of Significant Accounting Policies [Line Items]
Capitalized web development cost	$ 6,441	$ 5,369
Depreciation expense	6,403	6,449	$ 5,070
Property and equipment, net	11,630	11,597
Website Development Costs [Member]
Summary Of Significant Accounting Policies [Line Items]
Capitalized web development cost	4,861	5,539
Depreciation expense	6,580	6,421	$ 5,696
Property and equipment, net	$ 9,624	$ 11,343

Summary of Significant Accoun37

Summary of Significant Accounting Policies - Summary of Revenues from Four Revenue Groups (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Summary of revenues relating to public and private portal
Revenue	$ 192,129	$ 152,607	$ 148,320	$ 143,343	$ 162,727	$ 143,490	$ 140,400	$ 133,832	$ 636,399	$ 580,449	$ 515,293
Advertising and Sponsorship [Member]
Summary of revenues relating to public and private portal
Revenue									499,025	453,965	417,027
Advertising and Sponsorship [Member] | Biopharma and Medical Device [Member]
Summary of revenues relating to public and private portal
Revenue									371,220	329,329	304,018
Advertising and Sponsorship [Member] | OTC, CPG and Other [Member]
Summary of revenues relating to public and private portal
Revenue									127,805	124,636	113,009
Private Portal Services [Member]
Summary of revenues relating to public and private portal
Revenue									110,441	103,182	82,111
Information Services [Member]
Summary of revenues relating to public and private portal
Revenue									$ 26,933	$ 23,302	$ 16,155

Summary of Significant Accoun38

Summary of Significant Accounting Policies - Schedule of Net Income Per Common Shares (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Numerator:
Income from continuing operations - Basic	$ 27,461	$ 13,188	$ 13,371	$ 10,004	$ 15,154	$ 9,805	$ 9,716	$ 6,266	$ 64,024	$ 40,941	$ 15,116
Income from continuing operations - Diluted	$ 30,571	$ 15,849	$ 17,135	$ 10,868	18,918	$ 10,669	$ 10,580	$ 6,266	$ 78,129	44,397	$ 15,116
Income from discontinued operations, net of tax - Basic and Diluted					$ 1,122					$ 1,122
Denominator:
Weighted-average shares - Basic	36,583	36,721	36,705	36,393	36,427	37,960	37,819	39,268	36,600	37,869	46,830
Stock options and restricted stock	1,427	1,338	1,503	1,378	1,245	2,113	2,301	2,584	1,412	2,060	1,568
Adjusted weighted-average shares after assumed conversions - Diluted	51,338	49,958	53,618	43,465	53,082	45,757	45,801	41,852	52,653	45,614	48,398
Basic income per common share:
Income from continuing operations	$ 0.75	$ 0.36	$ 0.36	$ 0.27	$ 0.42	$ 0.26	$ 0.26	$ 0.16	$ 1.75	$ 1.08	$ 0.32
Income from discontinued operations					0.03					0.03
Net income - Basic					0.45	0.26	0.26	0.16	1.75	1.11	0.32
Diluted income per common share:
Income from continuing operations	$ 0.60	$ 0.32	$ 0.32	$ 0.25	0.36	0.23	0.23	0.15	1.48	0.97	0.31
Income from discontinued operations					0.02					0.03
Net income - Diluted					$ 0.38	$ 0.23	$ 0.23	$ 0.15	$ 1.48	$ 1	$ 0.31
1.50% Convertible Notes Due 2020 [Member]
Numerator:
Interest expense, net of tax	$ 864	$ 864	$ 864	$ 864	$ 864	$ 864	$ 864		$ 3,456	$ 3,456
Denominator:
Convertible note	5,694	5,694	5,694	5,694	5,694	5,684	5,681		5,694	5,685
2.50% Convertible Notes Due 2018 [Member]
Numerator:
Interest expense, net of tax	$ 1,797	$ 1,797	$ 1,797		$ 1,797				$ 7,189
Denominator:
Convertible note	6,205	6,205	6,205		6,205				6,205
2.25% Convertible Notes Due 2016 [Member]
Numerator:
Interest expense, net of tax	$ 449		$ 1,103		$ 1,103				$ 3,460
Denominator:
Convertible note	1,429		3,511		3,511				2,742

Summary of Significant Accoun39

Summary of Significant Accounting Policies - Schedule of Net Income Per Common Shares (Parenthetical) (Detail)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2011
1.50% Convertible Notes Due 2020 [Member]
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Interest on notes	1.50%	1.50%	1.50%
2.50% Convertible Notes Due 2018 [Member]
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Interest on notes	2.50%			2.50%
2.25% Convertible Notes Due 2016 [Member]
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Interest on notes	2.25%		2.25%	2.25%

Summary of Significant Accoun40

Summary of Significant Accounting Policies - Weighted Average Number of Potentially Dilutive Common Shares Excluded from Computation of Diluted Income Per Common Share (Detail) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average number of potentially dilutive common shares that were excluded from the computation of diluted income per common share	3,678	12,295	17,468
Options and Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average number of potentially dilutive common shares that were excluded from the computation of diluted income per common share	3,678	2,594	5,744
1.50% Convertible Notes Due 2020 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average number of potentially dilutive common shares that were excluded from the computation of diluted income per common share			556
2.25% Convertible Notes Due 2016 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average number of potentially dilutive common shares that were excluded from the computation of diluted income per common share		3,506	5,020
2.50% Convertible Notes Due 2018 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average number of potentially dilutive common shares that were excluded from the computation of diluted income per common share		6,195	6,148

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consolidated income from discontinued operations, net of tax	$ 1,122	$ 1,122
Porex [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Payments related to completion of audit		384
Consolidated income from discontinued operations, net of tax		$ 1,122
Porex [Member] | Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Remaining estimate of tax indemnification liability related to Porex included within liabilities of discontinued operations			$ 1,506

Convertible Notes - Additional

Convertible Notes - Additional Information (Detail) $ / shares in Units, $ in Thousands	Sep. 10, 2014shares$ / shares	Nov. 26, 2013USD ($)shares$ / shares	Sep. 11, 2013shares$ / shares	Apr. 04, 2012shares$ / shares	Mar. 14, 2011USD ($)shares$ / shares	Jan. 11, 2011USD ($)shares$ / shares	Sep. 30, 2015USD ($)	Dec. 31, 2015USD ($)shares	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)shares	Dec. 31, 2011
Debt Instrument [Line Items]
Proceeds from sale of notes										$ 291,823
Cash paid to repurchase common stock								$ 28,406	$ 128,748	220,298
Pre-tax loss on repurchase of notes							$ 2,058	$ 2,058		$ 4,871
2.50% Convertible Notes Due 2018 [Member]
Debt Instrument [Line Items]
Interest on convertible notes								2.50%			2.50%
Convertible notes								$ 400,000	400,000
2.50% Convertible Notes Due 2018 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Convertible notes due						$ 400,000
Interest on convertible notes						2.50%
Debt instrument, maturity date						Jan. 31, 2018
Proceeds from sale of notes						$ 387,345
Cash paid to repurchase common stock						$ 100,000
Common stock repurchased, shares | shares						1,920,490
Common stock repurchased, price per share | $ / shares						$ 52.07
Conversion price per share of common stock | $ / shares	$ 64.47		$ 64.61	$ 65.26		$ 66.13
Conversion rate of notes per thousand dollar of principal amount	15.5118		15.4764	15.3223		15.1220
Common stock available upon conversion | shares	6,204,720		6,190,560	6,128,920		6,048,800
Percentage of principal amount equal to repurchase price								100.00%
2.25% Convertible Notes Due 2016 [Member]
Debt Instrument [Line Items]
Interest on convertible notes								2.25%		2.25%	2.25%
Convertible notes									$ 252,232
2.25% Convertible Notes Due 2016 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Convertible notes due					$ 400,000
Interest on convertible notes					2.25%
Debt instrument, maturity date					Mar. 31, 2016
Proceeds from sale of notes					$ 387,400
Cash paid to repurchase common stock					$ 50,000
Common stock repurchased, shares | shares					868,507
Common stock repurchased, price per share | $ / shares					$ 57.57
Conversion price per share of common stock | $ / shares	$ 71.84		$ 72	$ 72.73	$ 73.69
Conversion rate of notes per thousand dollar of principal amount	13.9202		13.8884	13.7502	13.5704
Common stock available upon conversion | shares	3,511,120		5,555,360	5,500,080	5,428,160			1,429,354		3,503,099
Percentage of principal amount equal to repurchase price								100.00%
Pre-tax loss on repurchase of notes								$ 2,058		$ 4,871
Convertible notes								102,682		252,232
2.25% Convertible Notes Due 2016 [Member] | Senior Notes [Member] | Privately Negotiated Transaction [Member]
Debt Instrument [Line Items]
Convertible notes repurchased								149,550		100,000
Repurchased amount in cash open market								$ 151,038		101,750
2.25% Convertible Notes Due 2016 [Member] | Senior Notes [Member] | Open Market [Member]
Debt Instrument [Line Items]
Convertible notes repurchased										47,768
Repurchased amount in cash open market										$ 48,604
1.50% Convertible Notes Due 2020 [Member]
Debt Instrument [Line Items]
Interest on convertible notes								1.50%	1.50%	1.50%
Convertible notes								$ 300,000	$ 300,000
1.50% Convertible Notes Due 2020 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Convertible notes due		$ 300,000
Interest on convertible notes		1.50%
Debt instrument, maturity date		Dec. 1, 2020
Proceeds from sale of notes		$ 291,823
Conversion price per share of common stock | $ / shares	$ 52.69	$ 52.81
Conversion rate of notes per thousand dollar of principal amount	18.9795	18.9362
Common stock available upon conversion | shares	5,693,850	5,680,860
Percentage of principal amount equal to repurchase price								100.00%
Minimum percentage of consideration received or to be received by holders of common stock for repurchase option								90.00%

Long-Lived Assets - Components

Long-Lived Assets - Components of Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 289,833	$ 241,249
Less: accumulated depreciation	(208,806)	(181,676)
Property and equipment, net	81,027	59,573
Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	66,708	60,341
Property and equipment, net	11,630	11,597
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	69,973	63,541
Website Development Costs [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	62,784	57,922
Property and equipment, net	9,624	11,343
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	72,679	44,000
Office Equipment, Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	17,398	15,154
Land and Buildings [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 291	$ 291

Long-Lived Assets - Additional

Long-Lived Assets - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jul. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Goodwill And Intangible Assets [Line Items]
Depreciation expense		$ 27,200	$ 27,010	$ 24,335
Goodwill		202,980	202,980
Cash paid to acquire intangible assets	$ 3,182
Amortization expense		$ 3,321	$ 2,801	$ 2,271
Technology [Member]
Goodwill And Intangible Assets [Line Items]
Amortization period of assets	3 years

Long-Lived Assets - Schedule of

Long-Lived Assets - Schedule of Finite and Indefinite Lived Intangible Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Indefinite and finite lived intangible assets, Gross Carrying Amount	$ 74,887	$ 74,887
Intangible Assets, Accumulated Amortization	(63,993)	(60,672)
Indefinite and finite lived intangible assets, Net	10,894	14,215
Content [Member]
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Finite lived intangible assets, Gross Carrying Amount	15,954	15,954
Intangible Assets, Accumulated Amortization	(15,954)	(15,954)
Customer Relationships [Member]
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Finite lived intangible assets, Gross Carrying Amount	34,057	34,057
Intangible Assets, Accumulated Amortization	(29,218)	(27,126)
Finite lived intangible assets, Net	$ 4,839	$ 6,931
Intangible Assets, Weighted Average Remaining Useful Life	2 years 8 months 12 days	3 years 7 months 6 days
Technology and Patents [Member]
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Finite lived intangible assets, Gross Carrying Amount	$ 17,882	$ 17,882
Intangible Assets, Accumulated Amortization	(16,291)	(15,231)
Finite lived intangible assets, Net	$ 1,591	$ 2,651
Intangible Assets, Weighted Average Remaining Useful Life	1 year 6 months	2 years 6 months
Trade Names-Definitive Lives [Member]
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Finite lived intangible assets, Gross Carrying Amount	$ 2,530	$ 2,530
Intangible Assets, Accumulated Amortization	(2,530)	(2,361)
Finite lived intangible assets, Net		$ 169
Intangible Assets, Weighted Average Remaining Useful Life		1 year
Trade Names-Indefinite Lives [Member]
Acquired Finite And Indefinite Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets, Gross Carrying Amount	4,464	$ 4,464
Indefinite-lived intangible assets, Net	$ 4,464	$ 4,464

Long-Lived Assets - Schedule 46

Long-Lived Assets - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Detail) $ in Thousands	Dec. 31, 2015USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2,016	$ 3,120
2,017	2,044
2,018	$ 1,266

Accrued Expense - Components of

Accrued Expense - Components of Accrued Expense (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Payables and Accruals [Abstract]
Accrued compensation	$ 45,715	$ 38,856
Accrued outside services	10,775	11,089
Accrued marketing and distribution	5,383	4,442
Accrued interest	5,119	5,960
Other accrued liabilities	13,672	12,311
Accrued expenses	$ 80,664	$ 72,658

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	Mar. 08, 2015DefendantsPlaintiff	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Loss Contingencies [Line Items]
Rent expense for operating leases | $		$ 6,506	$ 9,194	$ 8,805
Amount related to lease incentives and the difference between rent expense and the rental amount payable for leases | $		$ 12,071	$ 10,605
Dual Diagnosis Treatment Center, et al. v. Blue Cross of California, et al. [Member]
Loss Contingencies [Line Items]
Number of plaintiffs | Plaintiff	6
Dual Diagnosis Treatment Center, et al. v. Blue Cross of California, et al. [Member] | Blue Cross Blue Shield [Member]
Loss Contingencies [Line Items]
Number of defendants | Defendants	28
Dual Diagnosis Treatment Center, et al. v. Blue Cross of California, et al. [Member] | Health and Benefit Plans [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Number of defendants | Defendants	41

Commitments and Contingencies49

Commitments and Contingencies - Schedule of Future Minimum Lease Commitments (Detail) $ in Thousands	Dec. 31, 2015USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,016	$ 14,773
2,017	15,122
2,018	14,826
2,019	14,035
2,020	14,414
Thereafter	33,697
Total minimum lease payments	$ 106,867

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Shares authorized under 2005 Plan	24,975,000
Common stock available for future grants	2,320,338
Proceeds from exercise of stock options	$ 21,939	$ 40,602	$ 29,724
Employee withholding tax paid	6,438	33,385	12,526
Combined value of stock options exercised and vested restricted stock	34,670	100,232	45,882
Stock-based compensation expense	33,743	$ 32,546	$ 38,550
Unrecognized stock-based compensation expense related to unvested awards	$ 56,930
Period for recognition of unrecognized stock based compensation expense	2 years 3 months 18 days
Percentage of tax benefit attributable to stock-based compensation	38.00%	39.00%	39.00%
Directors [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Stock-based compensation expense	$ 467	$ 315	$ 364
Stock Options [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Expiration period from grant date	10 years
Stock-based compensation expense	$ 21,336	21,117	24,483
Restricted Stock [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Stock-based compensation expense	$ 11,940	$ 11,114	$ 13,703
Minimum [Member] | Stock Options [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Share based compensation arrangement by share based payment award, award vesting period	2 years
Minimum [Member] | Restricted Stock [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Share based compensation arrangement by share based payment award, award vesting period	3 years
Maximum [Member] | Stock Options [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Share based compensation arrangement by share based payment award, award vesting period	5 years
Maximum [Member] | Restricted Stock [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Share based compensation arrangement by share based payment award, award vesting period	4 years

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Share-Based Compensation, Stock Options, Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Shares Outstanding, Beginning Balance	7,547,526	11,429,279	13,300,688
Granted, Shares	2,134,900	899,200	2,844,500
Exercised, Shares	(989,993)	(3,875,410)	(2,695,600)
Cancelled, Shares	(821,998)	(905,543)	(2,020,309)
Shares Outstanding, Ending Balance	7,870,435	7,547,526	11,429,279
Weighted Average Exercise Price Per Share, Outstanding, at the beginning of the period	$ 32.69	$ 29.12	$ 26.24
Vested and Exercisable, Shares	4,101,045
Weighted Average Exercise Price Per Share, Granted	$ 42.75	43.03	33.64
Weighted Average Exercise Price Per Share, Exercised	24.53	24.40	20.90
Weighted Average Exercise Price Per Share, Cancelled	38.68	33.42	27.50
Weighted Average Exercise Price Per Share, Outstanding, at the end of the period	35.81	$ 32.69	$ 29.12
Weighted Average Exercise Price per Share, Vested and exercisable at the end of the period	$ 32.22
Weighted Average Remaining Contractual Life (In Years), Outstanding	6 years 8 months 12 days
Weighted Average Remaining Contractual Life (In Years), Vested and exercisable at the end of the period	5 years 1 month 6 days
Aggregate Intrinsic Value, Outstanding	$ 99,384
Aggregate Intrinsic Value, Vested and Exercisable	$ 67,010

Stock-Based Compensation - Sc52

Stock-Based Compensation - Schedule of Share-Based Compensation, Stock Options, Activity (Parenthetical) (Detail)	Dec. 31, 2015$ / shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Market price of common stock	$ 48.30

Stock-Based Compensation - Summ

Stock-Based Compensation - Summarized Information with Respect to Options Outstanding and Options Exercisable (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Outstanding, Shares	7,870,435	7,547,526	11,429,279	13,300,688
Outstanding, Weighted Average Exercise Price Per Share	$ 35.81	$ 32.69	$ 29.12	$ 26.24
Outstanding, Weighted Average Remaining Contractual Life (In Years)	6 years 8 months 12 days
Exercisable Shares	4,101,045
Exercisable, Weighted Average Exercise Price Per Share	$ 32.22
$13.15 - $19.95 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, Lower Range Limit	13.15
Exercise Price, Upper Range Limit	$ 19.95
Outstanding, Shares	532,595
Outstanding, Weighted Average Exercise Price Per Share	$ 13.50
Outstanding, Weighted Average Remaining Contractual Life (In Years)	6 years 10 months 24 days
Exercisable Shares	465,720
Exercisable, Weighted Average Exercise Price Per Share	$ 13.31
$20.21 - $25.99 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, Lower Range Limit	20.21
Exercise Price, Upper Range Limit	$ 25.99
Outstanding, Shares	636,867
Outstanding, Weighted Average Exercise Price Per Share	$ 22.78
Outstanding, Weighted Average Remaining Contractual Life (In Years)	4 years 4 months 24 days
Exercisable Shares	497,217
Exercisable, Weighted Average Exercise Price Per Share	$ 22.80
$26.03 - $29.92 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, Lower Range Limit	26.03
Exercise Price, Upper Range Limit	$ 29.92
Outstanding, Shares	838,411
Outstanding, Weighted Average Exercise Price Per Share	$ 28.08
Outstanding, Weighted Average Remaining Contractual Life (In Years)	4 years
Exercisable Shares	791,961
Exercisable, Weighted Average Exercise Price Per Share	$ 28.07
$30.00 - $33.40 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, Lower Range Limit	30
Exercise Price, Upper Range Limit	$ 33.40
Outstanding, Shares	1,037,794
Outstanding, Weighted Average Exercise Price Per Share	$ 32.15
Outstanding, Weighted Average Remaining Contractual Life (In Years)	6 years 9 months 18 days
Exercisable Shares	703,044
Exercisable, Weighted Average Exercise Price Per Share	$ 31.64
$33.55 - $38.60 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, Lower Range Limit	33.55
Exercise Price, Upper Range Limit	$ 38.60
Outstanding, Shares	658,575
Outstanding, Weighted Average Exercise Price Per Share	$ 36.73
Outstanding, Weighted Average Remaining Contractual Life (In Years)	5 years 10 months 24 days
Exercisable Shares	465,187
Exercisable, Weighted Average Exercise Price Per Share	$ 36.85
$38.65 - $39.50 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, Lower Range Limit	38.65
Exercise Price, Upper Range Limit	$ 39.50
Outstanding, Shares	1,019,918
Outstanding, Weighted Average Exercise Price Per Share	$ 39.07
Outstanding, Weighted Average Remaining Contractual Life (In Years)	7 years 10 months 24 days
Exercisable Shares	326,258
Exercisable, Weighted Average Exercise Price Per Share	$ 39.05
$39.51 - $42.98 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, Lower Range Limit	39.51
Exercise Price, Upper Range Limit	$ 42.98
Outstanding, Shares	531,500
Outstanding, Weighted Average Exercise Price Per Share	$ 40.56
Outstanding, Weighted Average Remaining Contractual Life (In Years)	6 years 9 months 18 days
Exercisable Shares	170,500
Exercisable, Weighted Average Exercise Price Per Share	$ 40.84
$42.99 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, Lower Range Limit	$ 42.99
Outstanding, Shares	1,336,000
Outstanding, Weighted Average Exercise Price Per Share	$ 42.99
Outstanding, Weighted Average Remaining Contractual Life (In Years)	9 years 2 months 12 days
$43.05 - $46.46 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, Lower Range Limit	$ 43.05
Exercise Price, Upper Range Limit	$ 46.46
Outstanding, Shares	637,000
Outstanding, Weighted Average Exercise Price Per Share	$ 44.72
Outstanding, Weighted Average Remaining Contractual Life (In Years)	8 years 3 months 18 days
Exercisable Shares	134,200
Exercisable, Weighted Average Exercise Price Per Share	$ 45.46
$46.50 - $58.96 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, Lower Range Limit	46.50
Exercise Price, Upper Range Limit	$ 58.96
Outstanding, Shares	641,775
Outstanding, Weighted Average Exercise Price Per Share	$ 49.46
Outstanding, Weighted Average Remaining Contractual Life (In Years)	4 years 8 months 12 days
Exercisable Shares	546,958
Exercisable, Weighted Average Exercise Price Per Share	$ 49.70

Stock-Based Compensation - Sc54

Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%	0.00%	0.00%
Expected volatility, Minimum	41.00%	47.00%	43.00%
Expected volatility, Maximum	48.00%	49.00%	48.00%
Risk-free interest rate, Minimum	1.01%	1.16%	0.55%
Risk-free interest rate, Maximum	1.56%	1.72%	1.62%
Weighted-average fair value of options granted during the period	$ 16.26	$ 17.58	$ 13.95
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	4 years 1 month 6 days	4 years 2 months 12 days	4 years 6 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	4 years 8 months 12 days	5 years	5 years 1 month 6 days

Stock-Based Compensation - Sc55

Stock-Based Compensation - Schedule of Share-based Compensation, Restricted Stock Awards, Activity (Detail) - Restricted Stock [Member] - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted Stock Awards, Shares, Balance at the beginning of the year	904,083	1,184,961	932,386
Restricted Stock Awards, Shares, Granted	441,920	177,200	812,000
Restricted Stock Awards, Shares, Vested	(331,558)	(324,453)	(401,825)
Restricted Stock Awards, Shares, Forfeited	(159,600)	(133,625)	(157,600)
Restricted Stock Awards, Shares, Balance at the end of the year	854,845	904,083	1,184,961
Weighted Average Grant Date Fair Value, Balance at the beginning of the year	$ 35.58	$ 33.07	$ 31.69
Weighted Average Grant Date Fair Value, Granted	42.96	43.84	32.65
Weighted Average Grant Date Fair Value, Vested	35.72	32.70	32.57
Weighted Average Grant Date Fair Value, Forfeited	36.57	31.29	24.02
Weighted Average Grant Date Fair Value, Ending Balance	$ 39.17	$ 35.58	$ 33.07

Stock-Based Compensation - Sc56

Stock-Based Compensation - Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 33,743	$ 32,546	$ 38,550
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	21,336	21,117	24,483
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	11,940	11,114	13,703
Cost of Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	5,217	5,940	6,762
Sales and Marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	7,290	7,221	8,395
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	21,236	19,385	23,393
Other [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 467	$ 315	$ 364

Retirement Plans - Additional I

Retirement Plans - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]
Expense related to retirement plans	$ 4,495	$ 3,971	$ 3,903

Equity - Additional Information

Equity - Additional Information (Detail) $ / shares in Units, $ in Thousands

Sep. 09, 2014USD ($)$ / sharesshares

Oct. 21, 2013USD ($)$ / sharesshares

Sep. 10, 2013USD ($)$ / sharesshares

Sep. 30, 2015USD ($)

Nov. 30, 2014USD ($)

Apr. 30, 2014USD ($)

Mar. 31, 2014USD ($)

Feb. 28, 2014USD ($)

Oct. 31, 2011USD ($)

Dec. 31, 2015USD ($)$ / sharesshares

Dec. 31, 2014USD ($)shares

Dec. 31, 2013USD ($)shares

Nov. 14, 2014

Oct. 31, 2012$ / shares

Oct. 30, 2012$ / shares

Nov. 02, 2011$ / shares

Aug. 31, 2011USD ($)

Equity, Class of Treasury Stock [Line Items]

Common stock repurchased, total consideration

$ 28,406

$ 128,748

$ 219,729

Cash paid to repurchase common stock

$ 28,406

$ 128,748

$ 220,298

Right to purchase preferred stock, exercise price | $ / shares

$ 66.29

$ 153

Series A Junior Preferred Stock [Member]

Equity, Class of Treasury Stock [Line Items]

Preferred stock, par value | $ / shares

$ 0.01

Warrant to Purchase Series A Junior Preferred Stock [Member]

Equity, Class of Treasury Stock [Line Items]

Terms of Rights Agreement

1 year

Preferred stock purchase rights per outstanding share

1

Right to purchase preferred stock, exercise price | $ / shares

$ 153

Warrant to Purchase Series A Junior Preferred Stock [Member] | Series A Junior Preferred Stock [Member]

Equity, Class of Treasury Stock [Line Items]

Preferred shares authorized per purchase right | shares

0.001

2014 Tender Offer [Member]

Equity, Class of Treasury Stock [Line Items]

Common stock repurchased, shares | shares

2,000,000

Common stock repurchased, price per share | $ / shares

$ 48.50

Common stock repurchased, total consideration

$ 97,588

Costs directly attributable to repurchase of common stock

$ 588

2013 Tender Offer [Member]

Equity, Class of Treasury Stock [Line Items]

Common stock repurchased, shares | shares

5,000,000

Common stock repurchased, price per share | $ / shares

$ 34

Costs directly attributable to repurchase of common stock

$ 516

Common stock repurchased and retired, total consideration

$ 170,516

2011 Program [Member]

Equity, Class of Treasury Stock [Line Items]

Common stock repurchased, shares | shares

688,467

3,160,070

1,266,962

Stock repurchase program authorized additional amount

$ 27,451

$ 23,895

$ 30,000

$ 40,000

$ 50,000

$ 75,000

Cash paid to repurchase common stock

$ 28,406

$ 128,748

Stock repurchase program, remaining authorized repurchase amount

$ 34,056

2011 Program [Member] | Maximum [Member]

Equity, Class of Treasury Stock [Line Items]

Funds authorized to repurchase common stock

$ 75,000

2012 Program [Member]

Equity, Class of Treasury Stock [Line Items]

Common stock repurchased, shares | shares

39,857

Cash paid to repurchase common stock

$ 569

Carl C Icahn and Affiliates [Member]

Equity, Class of Treasury Stock [Line Items]

Common stock repurchased, shares | shares

5,527,433

Common stock repurchased, price per share | $ / shares

$ 32.08

Common stock repurchased, total consideration

$ 177,420

Costs directly attributable to repurchase of common stock

$ 100

Income Taxes - Significant Comp

Income Taxes - Significant Components of the Company's Deferred Tax Assets (Liabilities) (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Federal net operating loss carryforwards	$ 83,071	$ 91,000
State net operating loss carryforwards	33,320	35,488
Capital losses	292	458
Federal tax credits	28,555	56,096
Accrued expenses	19,086	17,919
Stock-based compensation	24,294	21,031
Intangible assets	3,610	3,570
Other	3,808	3,841
Total deferred tax assets	196,036	229,403
Valuation allowance	(142,604)	(157,644)
Net deferred tax assets	53,432	71,759
Deferred tax liabilities:
Property and equipment	(1,466)	(3,063)
Goodwill and indefinite-lived intangible asset	(33,465)	(30,975)
Other	(2,807)	(627)
Total deferred tax liabilities	(37,738)	(34,665)
Net deferred tax assets	15,694	37,094
Current deferred tax assets, net:
Current deferred tax assets, net of deferred tax liabilities	66,665	59,371
Valuation allowance	(50,539)	(41,224)
Current deferred tax assets, net	16,126	18,147
Non-current deferred tax (liabilities) assets, net:
Non-current deferred tax assets, net of deferred tax liabilities	91,633	135,367
Valuation allowance	(92,065)	(116,420)
Non-current deferred tax assets, net		18,947
Non-current deferred tax assets, net of deferred tax liabilities	91,633	135,367
Valuation allowance	(92,065)	(116,420)
Non-current deferred (liabilities), net	(432)
Net deferred tax assets	$ 15,694	$ 37,094

Income Taxes - Income Tax Provi

Income Taxes - Income Tax Provision (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Federal									$ 1,076	$ (622)	$ (73)
State									4,773	3,047	502
Foreign									268	369	141
Current income tax provision									6,117	2,794	570
Deferred:
Federal									(8,456)	12,570	10,683
State									743	2,147	2,387
Deferred income tax (benefit) provision									(7,713)	14,717	13,070
Reversal of valuation allowance applied to additional paid-in capital									37,443	13,196
Total income tax provision	$ 18,379	$ 9,080	$ 1,255	$ 7,133	$ 11,236	$ 7,275	$ 7,371	$ 4,825	$ 35,847	$ 30,707	$ 13,640

Income Taxes - Reconciliation b

Income Taxes - Reconciliation between Federal Statutory Rate and Effective Income Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
United States federal statutory rate	35.00%	35.00%	35.00%
State income taxes (net of federal benefit)	5.70%	7.40%	12.50%
Valuation allowance	(7.10%)	(3.30%)	(6.40%)
Non-deductible officer compensation	1.40%	2.20%	3.60%
Other	0.90%	1.60%	2.70%
Effective income tax rate	35.90%	42.90%	47.40%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	Nov. 25, 2008	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Valuation allowance reversed through additional paid-in capital			$ 37,443	$ 13,196
Deferred tax asset, state net operating loss carry forwards			33,320	35,488
Increase (Decrease) in valuation allowance for deferred tax asset			(15,040)	(16,948)
Reversal of valuation allowance through tax provision		$ 24,775
Net operating loss carryforwards for federal income tax purposes			615,000
Federal tax credits			66,767
Federal tax credits, unrecognized tax benefits			$ 44,128
Federal tax credits, unrecognized tax benefits, expiration dates			2017 through 2031
Expiration period of operating loss carryforwards			2021 through 2034
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration			$ 22,639
Excess tax benefits related to share-based payments, deferred tax assets			230,000
Excess tax benefits, adjustment related to share-based payments			460,000
Percentage of ownership in company's capital	50.00%
Unrecognized income tax benefits			14,815	13,553
Result of unrecognized income tax benefit if recognized			14,815	8,828
Accrued interest and penalties			738	581
Minimum [Member]
Reduction in unrecognized income tax benefits			100
Maximum [Member]
Reduction in unrecognized income tax benefits			200
Valuation Allowance, Operating Loss Carryforwards [Member]
Deferred tax asset, state net operating loss carry forwards			$ 1,455	1,311	$ 1,351
Valuation Allowance of Deferred Tax Assets [Member]
Valuation allowance reversed through additional paid-in capital				$ 1,359

Income Taxes - Activity of Unre

Income Taxes - Activity of Unrecognized Tax Benefits, Excluding Accrued Interest and Penalties (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Balance at the beginning of the year	$ 12,972	$ 13,392	$ 13,949
Increases related to prior year tax positions	776	15
Increases related to current year tax positions	394
Decreases related to prior year tax positions		(379)	(532)
Settlements	(15)
Expiration of the statute of limitations for the assessment of taxes	(50)	(56)	(25)
Balance at the end of the year	$ 14,077	$ 12,972	$ 13,392

Fair Value of Financial Instr64

Fair Value of Financial Instruments - Financial Assets Measured and Recorded at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents, Amortized Cost Basis	$ 641,165	$ 706,776	$ 824,880	$ 991,835
Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents, Amortized Cost Basis	641,165	706,776
Cash and cash equivalents, Fair Value	641,165	706,776
Cash and cash equivalents, Gross Unrealized Gains	0	0
Available-for-sale-security, Amortized cost basis	0	0
Available-for-sale-security, Fair value	598	1,603
Available-for-sale-security, Gross unrealized gains	$ 598	$ 1,603

Fair Value of Financial Instr65

Fair Value of Financial Instruments - Reconciliation of Beginning and Ending Balances of Available-for-sale Security (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Fair Value Disclosures [Abstract]
Fair value as of the beginning of the period	$ 1,603
Cash proceeds received	(139)
Gain included in earnings	139
Change in unrealized gains included in other comprehensive income	(1,005)
Fair value as of the end of the period	$ 598

Fair Value of Financial Instr66

Fair Value of Financial Instruments - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain on investments	$ 139	$ 139
Private Equity Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Amount		$ 6,471	$ 6,471

Fair Value of Financial Instr67

Fair Value of Financial Instruments - Carrying Value and Estimated Fair Value of Company's Convertible Notes that are Carried at Historical Cost (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
2.25% Convertible Notes Due 2016 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notes, Carrying Amount		$ 252,232
2.50% Convertible Notes Due 2018 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notes, Carrying Amount	$ 400,000	400,000
1.50% Convertible Notes Due 2020 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notes, Carrying Amount	300,000	300,000
Senior Notes [Member] | 2.25% Convertible Notes Due 2016 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notes, Carrying Amount	102,682		$ 252,232
Level 1 [Member] | Senior Notes [Member] | 2.25% Convertible Notes Due 2016 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notes, Carrying Amount	102,682	252,232
Notes, Fair Value	102,618	254,754
Level 1 [Member] | Senior Notes [Member] | 2.50% Convertible Notes Due 2018 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notes, Carrying Amount	400,000	400,000
Notes, Fair Value	416,000	399,000
Level 1 [Member] | Senior Notes [Member] | 1.50% Convertible Notes Due 2020 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notes, Carrying Amount	300,000	300,000
Notes, Fair Value	$ 340,566	$ 299,250

Fair Value of Financial Instr68

Fair Value of Financial Instruments - Carrying Value and Estimated Fair Value of Company's Convertible Notes that are Carried at Historical Cost (Parenthetical) (Detail)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Nov. 26, 2013	Dec. 31, 2011	Mar. 14, 2011	Jan. 11, 2011
2.25% Convertible Notes Due 2016 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest on convertible notes	2.25%		2.25%		2.25%
2.25% Convertible Notes Due 2016 [Member] | Senior Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest on convertible notes						2.25%
2.25% Convertible Notes Due 2016 [Member] | Level 1 [Member] | Senior Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest on convertible notes	2.25%	2.25%
2.50% Convertible Notes Due 2018 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest on convertible notes	2.50%				2.50%
2.50% Convertible Notes Due 2018 [Member] | Senior Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest on convertible notes							2.50%
2.50% Convertible Notes Due 2018 [Member] | Level 1 [Member] | Senior Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest on convertible notes	2.50%	2.50%
1.50% Convertible Notes Due 2020 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest on convertible notes	1.50%	1.50%	1.50%
1.50% Convertible Notes Due 2020 [Member] | Senior Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest on convertible notes				1.50%
1.50% Convertible Notes Due 2020 [Member] | Level 1 [Member] | Senior Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest on convertible notes	1.50%	1.50%

Supplemental Disclosures of C69

Supplemental Disclosures of Cash Flow Information - Supplemental Disclosure of Cash Flow Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Supplemental Disclosure of Cash Flow Information:
Interest paid	$ 19,792	$ 20,225	$ 19,038
Taxes paid, net	$ 2,850	$ 277	$ 274

Quarterly Financial Data (Una70

Quarterly Financial Data (Unaudited) - Quarterly Financial Data (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Revenue	$ 192,129	$ 152,607	$ 148,320	$ 143,343	$ 162,727	$ 143,490	$ 140,400	$ 133,832	$ 636,399	$ 580,449	$ 515,293
Cost of operations	69,475	59,552	60,407	57,877	60,676	56,398	54,456	52,564	247,311	224,094	209,740
Sales and marketing	40,129	32,850	32,570	32,476	36,978	32,950	33,321	32,911	138,025	136,160	127,997
General and administrative	24,183	22,942	23,002	21,453	24,756	23,243	22,339	23,781	91,580	94,119	93,220
Depreciation and amortization	7,418	7,266	7,592	8,245	7,774	7,667	7,042	7,328	30,521	29,811	26,606
Interest income	15	10	9	17	18	19	17	15	51	69	76
Interest expense	5,099	5,681	6,171	6,172	6,171	6,171	6,172	6,172	23,123	24,686	22,826
Loss on convertible notes		2,058							2,058		4,871
Gain on investments			139						139
Other expense			4,100						4,100		1,353
Income from continuing operations before income tax provision	45,840	22,268	14,626	17,137	26,390	17,080	17,087	11,091	99,871	71,648	28,756
Income tax provision	18,379	9,080	1,255	7,133	11,236	7,275	7,371	4,825	35,847	30,707	13,640
Income from continuing operations					15,154	9,805	9,716	6,266	64,024	40,941	15,116
Income from discontinued operations, net of tax					1,122					1,122
Net income	$ 27,461	$ 13,188	$ 13,371	$ 10,004	$ 16,276	$ 9,805	$ 9,716	$ 6,266	$ 64,024	$ 42,063	$ 15,116
Basic income per common share:
Income from continuing operations	$ 0.75	$ 0.36	$ 0.36	$ 0.27	$ 0.42	$ 0.26	$ 0.26	$ 0.16	$ 1.75	$ 1.08	$ 0.32
Income from discontinued operations					0.03					0.03
Net income					0.45	0.26	0.26	0.16	1.75	1.11	0.32
Net income per common share - Basic	0.75	0.36	0.36	0.27	0.42	0.26	0.26	0.16	1.75	1.08	0.32
Diluted income per common share:
Income from continuing operations	0.60	0.32	0.32	0.25	0.36	0.23	0.23	0.15	1.48	0.97	0.31
Income from discontinued operations					0.02					0.03
Net income					0.38	0.23	0.23	0.15	1.48	1	0.31
Net income per common share - Diluted	$ 0.60	$ 0.32	$ 0.32	$ 0.25	$ 0.36	$ 0.23	$ 0.23	$ 0.15	$ 1.48	$ 0.97	$ 0.31
Numerator:
Income from continuing operations - Basic	$ 27,461	$ 13,188	$ 13,371	$ 10,004	$ 15,154	$ 9,805	$ 9,716	$ 6,266	$ 64,024	$ 40,941	$ 15,116
Income from continuing operations - Diluted	$ 30,571	$ 15,849	$ 17,135	$ 10,868	18,918	$ 10,669	$ 10,580	$ 6,266	$ 78,129	44,397	$ 15,116
Income from discontinued operations, net of tax - Basic and Diluted					$ 1,122					$ 1,122
Denominator:
Weighted-average shares - Basic	36,583	36,721	36,705	36,393	36,427	37,960	37,819	39,268	36,600	37,869	46,830
Stock options and restricted stock	1,427	1,338	1,503	1,378	1,245	2,113	2,301	2,584	1,412	2,060	1,568
Adjusted weighted-average shares after assumed conversions - Diluted	51,338	49,958	53,618	43,465	53,082	45,757	45,801	41,852	52,653	45,614	48,398
1.50% Convertible Notes Due 2020 [Member]
Numerator:
Interest expense on Notes, net of tax	$ 864	$ 864	$ 864	$ 864	$ 864	$ 864	$ 864		$ 3,456	$ 3,456
Denominator:
Convertible notes, Shares	5,694	5,694	5,694	5,694	5,694	5,684	5,681		5,694	5,685
2.50% Convertible Notes Due 2018 [Member]
Numerator:
Interest expense on Notes, net of tax	$ 1,797	$ 1,797	$ 1,797		$ 1,797				$ 7,189
Denominator:
Convertible notes, Shares	6,205	6,205	6,205		6,205				6,205
2.25% Convertible Notes Due 2016 [Member]
Numerator:
Interest expense on Notes, net of tax	$ 449		$ 1,103		$ 1,103				$ 3,460
Denominator:
Convertible notes, Shares	1,429		3,511		3,511				2,742

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Allowance for Doubtful Accounts [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Year	$ 631	$ 793	$ 1,304
Charged to Costs and Expenses	874	577	283
Write-offs	(465)	(739)	(794)
Balance at End of Year	1,040	631	793
Valuation Allowance of Deferred Tax Assets [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Year	157,644	174,592	176,403
Charged to Costs and Expenses	(7,061)	(2,350)	(1,831)
Other	(7,979)	(14,598)	20
Balance at End of Year	$ 142,604	$ 157,644	$ 174,592